(FILE 'HOME' ENTERED AT 11:51:21 ON 30 MAY 2002)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 11:51:32 ON 30 MAY 2002

L1	56826	S	ANTIMICROBIAL ACTIVITY
L2	33736	S	ANTIFUNGAL ACTIVITY
L3	102478	S	SUBSTANCE P
L4	39	S	L1 AND L3
L5	19	S	L2 AND L3
L6	39	DUP REM	L4 (0 DUPLICATES REMOVED)
L7	19	DUP REM	L5 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 11:59:34 ON 30 MAY 2002

=>

L9 ANSWER 1 OF 65 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1993:500498 BIOSIS
DOCUMENT NUMBER: PREV199396124505
TITLE: Inhibition of murine intestinal inflammation by anti-**substance P** antibody.
AUTHOR(S): Agro, Albert; Stanisz, Andrzej M. (1)
CORPORATE SOURCE: (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada
SOURCE: Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126. ISSN: 0896-0623.
DOCUMENT TYPE: Article
LANGUAGE: English

L9 ANSWER 2 OF 65 CABA COPYRIGHT 2002 CABI
ACCESSION NUMBER: 88:14558 CABA
DOCUMENT NUMBER: 881340734
TITLE: Inhibitory effects of levamisole- and tetramisole-hydrochloride (in vitro) on Prototheca zopfii and **Candida albicans**
Hemmwirkung von Levamisol- und Tetramisolhydrochlorid in vitro gegen Prototheca zopfii und **Candida albicans**
AUTHOR: Bergmann, A.
CORPORATE SOURCE: Wissenchaftsbereich Microbiologie und Tierseuchen, Sektion Tierproduction und Veterinarmedizin der Karl-Marx Universitat, Leipzig, German Democratic Republic.
SOURCE: Monatshefte fur Veterinarmedizin, (1987) Vol. 42, No. 16, pp. 599-602. 7 ref.
DOCUMENT TYPE: Journal
LANGUAGE: German
SUMMARY LANGUAGE: English; Russian

L9 ANSWER 3 OF 65 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:216943 CAPLUS
DOCUMENT NUMBER: 130:236482
TITLE: Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and detection of TABM in disease states
INVENTOR(S): Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9914243	A1	19990325	WO 1998-AU765	19980916
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9890558	A1	19990405	AU 1998-90558	19980916

PRIORITY APPLN. INFO.:		
US 1997-59047P	P	19970916
AU 1998-5850	A	19980911
WO 1998-AU765	W	19980916

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 65 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:237581 CAPLUS
DOCUMENT NUMBER: 120:237581
TITLE: Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification
INVENTOR(S): Mitsuhashi, Masato; Cooper, Allan
PATENT ASSIGNEE(S): Hitachi Chemical Company Ltd., Japan
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402636	A1	19940203	WO 1993-US999	19930129
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 652971	A1	19950517	EP 1993-905793	19930129
R: CH, DE, FR, GB, IT, LI				
JP 07509361	T2	19951019	JP 1993-504409	19930129
US 5580971	A	19961203	US 1995-379081	19950126
US 5639612	A	19970617	US 1995-379078	19950126
PRIORITY APPLN. INFO.:			US 1992-922522	19920728
			US 1992-974406	19921112
			WO 1993-US999	19930129

L9 ANSWER 5 OF 65 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95024893 EMBASE
DOCUMENT NUMBER: 1995024893
TITLE: High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.
AUTHOR: Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.
CORPORATE SOURCE: Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy
SOURCE: Pediatric Allergy and Immunology, (1994) 5/4 (240-243). ISSN: 0905-6157 CODEN: PALUEE
COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation
LANGUAGE: English
SUMMARY LANGUAGE: English

L9 ANSWER 6 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 2002:407170 SCISEARCH
THE GENUINE ARTICLE: 547ZQ
TITLE: Dermal application of jet fuel suppresses secondary immune reactions
AUTHOR: Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)
CORPORATE SOURCE: Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA
COUNTRY OF AUTHOR: USA

SOURCE: TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 7 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 2001:896861 SCISEARCH
THE GENUINE ARTICLE: 488ZW
TITLE: Induction of histamine release from rat peritoneal mast cells by histatins
AUTHOR: Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K
CORPORATE SOURCE: Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan
COUNTRY OF AUTHOR: Japan
SOURCE: BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.
Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.
ISSN: 0918-6158.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 8 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 97:368347 SCISEARCH
THE GENUINE ARTICLE: WX501
TITLE: Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides
AUTHOR: Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)
CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA
COUNTRY OF AUTHOR: SPAIN; INDIA
SOURCE: PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0196-9781.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 54
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 9 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 93:689339 SCISEARCH
THE GENUINE ARTICLE: MF885
TITLE: STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT

AUTHOR: DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A; GOMARIZ R P
CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3, SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR, MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN
COUNTRY OF AUTHOR: SPAIN
SOURCE: REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353.
ISSN: 0167-0115.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 44
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 10 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 93:606596 SCISEARCH
THE GENUINE ARTICLE: LZ829
TITLE: STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF PROTEIN-KINASE-C
AUTHOR: DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CORPORATE SOURCE: UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ INSALUD, SERV BIOQUIM, MADRID, SPAIN
COUNTRY OF AUTHOR: SPAIN
SOURCE: IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265.
ISSN: 0019-2805.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 38
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

=> d bib ab 19 1-10

L9 ANSWER 1 OF 65 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1993:500498 BIOSIS
DN PREV199396124505
TI Inhibition of murine intestinal inflammation by anti-**substance P** antibody.
AU Agro, Albert; Stanisz, Andrzej M. (1)
CS (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada
SO Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
ISSN: 0896-0623.
DT Article
LA English
AB Several neuropeptides have recently been shown to affect various aspects of the inflammatory process. Among these, the neuropeptide **substance P** posseses a host of immune modifying actions, which include the enhancement of lymphocyte activity, macrophage function, and neutrophil chemotaxis. The role of **substance P** during inflamed states has, as yet, not been fully described. Here, in T. spiralis-infected mice, we parallel increased levels of **substance P** both locally, (the gut) and peripherally (serum) with decreased lymphocyte responsiveness. Upon the introduction of in vivo antisubstance P antibody during the infection, levels of **substance P** , gastrointestinal inflammation, and lymphocyte proliferation are significantly restored to baseline (noninfected) levels. These findings suggest that the neuropeptide **substance P** plays an important role in promoting inflammation. It also offers the basis for

future pharmacological interventions.

L9 ANSWER 2 OF 65 CABA COPYRIGHT 2002 CABI
AN 88:14558 CABA
DN 881340734
TI Inhibitory effects of levamisole- and tetramisole-hydrochloride (in vitro) on Prototheca zopfii and **Candida albicans**
Hemmwirkung von Levamisol- und Tetramisolhydrochlorid in vitro gegen Prototheca zopfii und **Candida albicans**
AU Bergmann, A.
CS Wissenchaftsbereich Microbiologie und Tierseuchen, Sektion Tierproduction und Veterinarmedizin der Karl-Marx Universitat, Leipzig, German Democratic Republic.
SO Monatshefte fur Veterinarmedizin, (1987) Vol. 42, No. 16, pp. 599-602. 7 ref.
DT Journal
LA German
SL English; Russian
AB Agar gel and paper disc diffusion tests were performed on 5 P. zopfii strs. obtained from cases of mastitis and 5 C. **albicans** strs. obtained from pathological material from various animal species. Levamisol hydrochloride was clearly shown to be the better of the 2 active **substances. P.** zopfii proved to be more sensitive than C. **albicans**. A comparison of the paper disc diffusion test with antifungal agents used in human medicine revealed that 4 of 5 P. zopfii strs. were more sensitive to tetramisol hydrochloride. Levamisol hydrochloride was found to be superior to nystatin in its action against C. **albicans**, but less so when compared with amphotericin B. Miconazole showed no antifungal effect against all P. zopfii strs.

L9 ANSWER 3 OF 65 CAPLUS COPYRIGHT 2002 ACS
AN 1999:216943 CAPLUS
DN 130:236482
TI Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and detection of TABM in disease states
IN Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes
PA USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914243	A1	19990325	WO 1998-AU765	19980916
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9890558	A1	19990405	AU 1998-90558	19980916
PRAI	US 1997-59047P	P	19970916		
	AU 1998-5850	A	19980911		
	WO 1998-AU765	W	19980916		

AB The present invention relates generally to immunointeractive mols. and their in the detection and/or purifn. of T-cell antigen binding mols. (TABMs). In a specific example, the authors disclose the prepn. and characterization of a monoclonal antibody to TABM. In a second example, transforming growth factor-.beta. is shown to bind TABM and to be activated on TABM binding to its cognate antigen. The ability to det. the presence and levels of particular TABMs may provide useful diagnostic

procedures for a variety of disease conditions.
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 65 CAPLUS COPYRIGHT 2002 ACS
AN 1994:237581 CAPLUS
DN 120:237581
TI Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification
IN Mitsuhashi, Masato; Cooper, Allan
PA Hitachi Chemical Company Ltd., Japan
SO PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9402636	A1	19940203	WO 1993-US999	19930129
	W: CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 652971	A1	19950517	EP 1993-905793	19930129
	R: CH, DE, FR, GB, IT, LI				
	JP 07509361	T2	19951019	JP 1993-504409	19930129
	US 5580971	A	19961203	US 1995-379081	19950126
	US 5639612	A	19970617	US 1995-379078	19950126
PRAI	US 1992-922522		19920728		
	US 1992-974406		19921112		
	WO 1993-US999		19930129		

AB A method for detecting the presence of a particular organism, infectious agent, or component of a cell or organism in a biol. sample by nucleic acid hybridization is described. A hybridization probe for the target sequence is immobilized on a solid support, such as microtiter well, and the target sequence is then hybridized to the immobilized probe. A second, labeled probe is then hybridized to this support-polynucleotide structure and binding of this probe is used to quantify the target sequence. Sensitivity of the system may be improved by amplification of the bound or free target polynucleotide. Also included in the present invention are polynucleotide probes and primers and the use of an H-site model and algorithm for the design of these probes and primers with an optimized matching of Tm's based upon related sequences available in data banks.

L9 ANSWER 5 OF 65 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95024893 EMBASE
DN 1995024893
TI High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.
AU Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.
CS Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy
SO Pediatric Allergy and Immunology, (1994) 5/4 (240-243).
ISSN: 0905-6157 CODEN: PALUEE
CY Denmark
DT Journal; Article
FS 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation
LA English
SL English
AB The specificity of IgA against food, inhalant, bacterial and fungine antigens as well as for HIV-1 proteins was investigated in 14 HIV-1-infected children (CDC stage P-2) and 15 controls. IgA against food-

and inhalant antigens as well as against tetanus toxoid were significantly more often present in the HIV positive children than in controls. No difference between the two groups was present for IgA against **Candida albicans**. A significant increase of **substance P**, a strong IgA synthesis inducing neuropeptide, was demonstrated in the plasma of HIV-1 infected children. In conclusion, high levels of IgA seem to reflect a complex immune dysfunction in which many factors are involved. The importance of neuroimmune dysregulation is discussed.

L9 ANSWER 6 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 2002:407170 SCISEARCH
GA The Genuine Article (R) Number: 547ZQ
TI Dermal application of jet fuel suppresses secondary immune reactions
AU Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)
CS Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA
CYA USA
SO TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.
DT Article; Journal
LA English
REC Reference Count: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Applying military jet fuel (JP-8) to the skin of mice activates systemic immune suppression. In all of our previous experiments, JP-8 was applied to immunologically naive mice. The effect of jet fuels on established immune reactions, such as immunological memory, is unknown. The focus of the experiments presented here was to test the hypothesis that jet fuel exposure [both JP-8 and commercial jet fuel (Jet-A)] suppresses established immune reactions. Mice were immunized with the opportunistic fungal pathogen **Candida albicans** and, at different times after immunization (10 to 30 days), various doses of undiluted JP-8 or Jet-A were applied to their skin. Both the elicitation of delayed-type hypersensitivity (DTH) (mice challenged 10 days after immunization) and immunological memory (mice challenged 30 days after immunization) were significantly suppressed in a dose-dependent manner. Dermal exposure to either multiple small doses (50 mul over 4 days) or a single large dose (approximate to200-300 mul) of JP-8 and/or Jet-A suppressed DTH to C. **albicans**. The mechanism by which dermal application of JP-8 and Jet-A suppresses immunological memory involves the release of immune biologic response modifiers. Blocking the production of prostaglandin E, by a selective cyclooxygenase-2 inhibitor (SC 236) significantly reversed jet fuel-induced suppression of immunologic memory. These findings indicate, for the first time, that dermal exposure to commercial jet fuel (Jet-A) suppresses the immune response. In addition, the data reported here expand on previous findings by suggesting that jet fuel exposure may depress the protective effect of prior vaccination. (C) 2002 Elsevier Science (USA).

L9 ANSWER 7 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 2001:896861 SCISEARCH
GA The Genuine Article (R) Number: 488ZW
TI Induction of histamine release from rat peritoneal mast cells by histatins
AU Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K
CS Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya

Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan
CYA Japan
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.
Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.
ISSN: 0918-6158.
DT Article; Journal
LA English
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Human salivary histatins (Hsts), which belong to a salivary polypeptide family, have potent antifungal activity against **Candida albicans** and Cryptococcus neoformans, and are expected to be useful as therapeutic reagents against **Candida** species. However, little is known about the effect of Hsts on host immune systems. Thus we conducted a series of in vitro experiments with rat mast cells to determine whether histatin 5 (Hst 5) or histatin 8 (Hst 8) has a histamine-releasing effect on mast cells. Both Hst 5 and Hst 8 induced histamine release from rat peritoneal mast cells in a dose-dependent manner (10(-9) to 10(-5) m). Hst 5 had a stronger releasing effect than Hst 8. The histamine release induced by Hst 5 (10(-6) M) was increased by the presence of 0.5 mm Ca2+, but decreased by 2 mm Ca2+. Alternatively, the histamine release induced by Hst 8 (10(-6) M) was inhibited by the presence of Ca2+ (0.5 to 2 mm). These results suggest that Hsts have limited usefulness as therapeutic agents due to induction of histamine release from mast cells.

L9 ANSWER 8 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 97:368347 SCISEARCH
GA The Genuine Article (R) Number: WX501
TI Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides
AU Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA
CYA SPAIN; INDIA
SO PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0196-9781.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 54
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The effects of CCK-8s and desulfated CCK-8 at concentrations ranging from 10-(14) to 10(-6) M were studied in vitro on several functions of human peripheral neutrophils: adherence to substrate, mobility (spontaneous and directed by a chemical gradient or chemotaxis), ingestion of inert particles (latex beads) or cells (**Candida albicans**), and production of superoxide anion measured by the nitroblue tetrazolium reduction test. The effect of CCK-8s on intracellular levels of cAMP was investigated as well as the implication of calcium in the action of CCK-8s on phagocytic function using stimulants and inhibitors of both intracellular and extracellular calcium channels. The two peptides, at concentrations from 10-(12) to 10(-8) M, inhibited significantly both mobility and ingestion capacities and increased adherence to substrate. A dose-response relationship was observed with a maximum inhibition of neutrophil functions at 10(-10) M. CCK-8s and desulfated CCK-8 induced in these cells a significant, but transient,

increase of cAMP levels at 60 s. Moreover, CCK-8s was found to inhibit completely the stimulation of latex bead phagocytosis in neutrophils produced by the calcium ionophore A23187. These results suggest that CCK-8 is a negative modulator of several neutrophil functions and that the inhibition of these activities could be carried out through an increase of the intracellular cAMP levels and a decrease of the extracellular calcium input. (C) 1997 Elsevier Science Inc.

L9 ANSWER 9 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 93:689339 SCISEARCH
GA The Genuine Article (R) Number: MF885
TI STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT
AU DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A; GOMARIZ R P
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3, SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR, MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353. ISSN: 0167-0115.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 44
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The action of vasoactive intestinal peptide (VIP) on macrophages has not yet been studied, although there are studies that show an inhibitory action of VIP on lymphocyte functions. The present study shows that VIP in a range from 10(-12) to 10(-7) M increased significantly the phagocytosis and digestion capacities of rat peritoneal macrophages. The most effective concentration of VIP was 10(-9) M followed by 10(-8) M. With respect to the phagocytic capacity, the ingestion of cells (**Candida albicans**) or inert particles (latex beads) was stimulated significantly with all the concentrations used. The digestion capacity was analyzed through the production of superoxide anion, measured by the reduction of nitroblue tetrazolium (NBT). As with phagocytic capacity, superoxide anion production was increased by VIP in non-stimulated macrophages (incubated without latex beads) and even more in stimulated cells (incubated in the presence of latex beads). The study of the mechanism of action of this neuropeptide showed that protein kinase C (PKC) was activated in the presence of VIP concentrations from 10(-10) to 10(-8) M in a similar way to that found with a specific PKC activator such as phorbol myristate acetate (PMA, 50 ng/ml). PMA also stimulated significantly the phagocytosis and digestion capacities of rat macrophages. By contrast, a PKC inhibitor, retinal (20 muM), decreased significantly the phagocytosis and digestion capacities. These data show that VIP could stimulate these macrophage functions through PKC activation.

L9 ANSWER 10 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 93:606596 SCISEARCH
GA The Genuine Article (R) Number: LZ829
TI STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF PROTEIN-KINASE-C
AU DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CS UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ INSALUD, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265. ISSN: 0019-2805.
DT Article; Journal
FS LIFE
LA ENGLISH

REC Reference Count: 38
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The peptides neuropeptide Y (NPY) and peptide YY (PYY) at concentrations from 10(-12) M to 10(-8) M have been shown in this study to stimulate significantly, in vitro, several functions of resting peritoneal macrophages from BALB/c mice: adherence to substrate, chemotaxis, ingestion of inert particles (latex beads) and foreign cells (**Candida albicans**), and production of superoxide anion measured by nitroblue tetrazolium reduction. A dose-response relationship was observed, with a maximal stimulation of the macrophage functions studied at 10(-10) M. These effects seem to be produced by specific receptors for the neuropeptides studied in peritoneal macrophages. Whereas the two peptides induced no change of intracellular cyclic AMP, they caused a significant stimulation of protein kinase C (PKC) in murine macrophages. These results suggest that NPY and PYY produce their effects on macrophage function through PKC activation.

=> d his

(FILE 'HOME' ENTERED AT 13:01:06 ON 30 MAY 2002)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 13:01:31 ON 30 MAY 2002

```
L1       102478 S SUBSTANCE P
L2       193060 S CANDIDA
L3          167 S L1 AND L2
L4          166 DUP REM L3 (1 DUPLICATE REMOVED)
L5          128 S L4 AND PREVENT?
L6          153 S L4 AND INHIBIT?
L7            3 S L6 AND FUNGAL GROWTH
L8            0 S L4 AND INHIBIT FUNGAL GROWTH
L9           65 S L4 AND ALBICANS
```

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10 65 DUP REM L9 (0 DUPLICATES REMOVED)

=> d ibib l10 bib ab 1-65

L10 ANSWER 1 OF 65 USPATFULL

ACCESSION NUMBER:	2002:120021 USPATFULL
TITLE:	Method for making multispecific antibodies having heteromultimeric and common components
INVENTOR(S):	Arathoon, W. Robert, San Mateo, CA, UNITED STATES Carter, Paul J., San Francisco, CA, UNITED STATES Merchant, Anne M., San Bruno, CA, UNITED STATES Presta, Leonard G., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S):	Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002062010	A1	20020523
APPLICATION INFO.:	US 2001-863693	A1	20010523 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-70166, filed on 30 Apr 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46816P	19970502 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 3173
AN 2002:120021 USPATFULL
TI Method for making multispecific antibodies having heteromultimeric and common components
IN Arathoon, W. Robert, San Mateo, CA, UNITED STATES
Carter, Paul J., San Francisco, CA, UNITED STATES
Merchant, Anne M., San Bruno, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002062010 A1 20020523
AI US 2001-863693 A1 20010523 (9)
RLI Continuation of Ser. No. US 1998-70166, filed on 30 Apr 1998, PENDING
PRAI US 1997-46816P 19970502 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3173
AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method futher involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.

L10 ANSWER 2 OF 65 USPATFULL
ACCESSION NUMBER: 2002:106404 USPATFULL
TITLE: Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
INVENTOR(S): Cuttitta, Frank, Adamstown, MD, UNITED STATES
Martinez, Alfredo, McLean, VA, UNITED STATES
Miller, Mae Jean, Monrovia, MD, UNITED STATES
Unsworth, Edward J., Kensington, MD, UNITED STATES
Hook, William, Wheaton, MD, UNITED STATES
Walsh, Thomas, Bethesda, MD, UNITED STATES
Gray, Karen, Gaithersburg, MD, UNITED STATES
Macri, Charles, Kensington, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055615	A1	20020509
APPLICATION INFO.:	US 2001-931700	A1	20010816 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-11922, filed on 17 Feb 1998, GRANTED, Pat. No. US 6320022

NUMBER	DATE

PRIORITY INFORMATION: WO 1996-US13286 19960816
US 1995-2514P 19950818 (60)
US 1995-2936P 19950830 (60)
US 1996-13172P 19960312 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 2311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:106404 USPATFULL
TI Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
IN Cuttitta, Frank, Adamstown, MD, UNITED STATES
Martinez, Alfredo, McLean, VA, UNITED STATES
Miller, Mae Jean, Monrovia, MD, UNITED STATES
Unsworth, Edward J., Kensington, MD, UNITED STATES
Hook, William, Wheaton, MD, UNITED STATES
Walsh, Thomas, Bethesda, MD, UNITED STATES
Gray, Karen, Gaithersburg, MD, UNITED STATES
Macri, Charles, Kensington, MD, UNITED STATES
PI US 2002055615 A1 20020509
AI US 2001-931700 A1 20010816 (9)
RLI Division of Ser. No. US 1998-11922, filed on 17 Feb 1998, GRANTED, Pat. No. US 6320022
PRAI WO 1996-US13286 19960816
US 1995-2514P 19950818 (60)
US 1995-2936P 19950830 (60)
US 1996-13172P 19960312 (60)
DT Utility
FS APPLICATION
LREP MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 2311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for Tpeptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.

L10 ANSWER 3 OF 65 USPATFULL
ACCESSION NUMBER: 2002:105676 USPATFULL
TITLE: Anti-IgE antibodies
INVENTOR(S): Lowman, Henry B., El Granada, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
Jardieu, Paula M., San Mateo, CA, UNITED STATES
Lowe, John, Daly City, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002054878	A1	20020509
APPLICATION INFO.:	US 2001-920171	A1	20010801 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED, Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, GRANTED, Pat. No. US 5994511
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 5846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:105676 USPATFULL
TI Anti-IgE antibodies
IN Lowman, Henry B., El Granada, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
Jardieu, Paula M., San Mateo, CA, UNITED STATES
Lowe, John, Daly City, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002054878 A1 20020509
AI US 2001-920171 A1 20010801 (9)
RLI Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED, Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, GRANTED, Pat. No. US 5994511
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 5846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 4 OF 65 USPATFULL
ACCESSION NUMBER: 2002:54627 USPATFULL
TITLE: Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto
INVENTOR(S): Rosenberg, E. William, Memphis, TN, UNITED STATES
Noah, Patricia W., Germantown, TN, UNITED STATES
Skinner, Robert B., JR., Memphis, TN, UNITED STATES
Mandrell, Timothy D., Memphis, TN, UNITED STATES
Narula, Jagat, Philadelphia, PA, UNITED STATES
Handorf, Charles R., Memphis, TN, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2002031788 A1 20020314
APPLICATION INFO.: US 2001-789102 A1 20010220 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-183647P	20000218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1173
CAS INDEXING IS AVAILABLE FOR THIS PATENT..
AN 2002:54627 USPATFULL
TI Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto
IN Rosenberg, E. William, Memphis, TN, UNITED STATES
Noah, Patricia W., Germantown, TN, UNITED STATES
Skinner, Robert B., JR., Memphis, TN, UNITED STATES
Mandrell, Timothy D., Memphis, TN, UNITED STATES
Narula, Jagat, Philadelphia, PA, UNITED STATES
Handorf, Charles R., Memphis, TN, UNITED STATES
PI US 2002031788 A1 20020314
AI US 2001-789102 A1 20010220 (9)
PRAI US 2000-183647P 20000218 (60)
DT Utility
FS APPLICATION
LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for diagnosing a systemic or autoimmune disorder and methods for treating the same by inducing the production of or otherwise providing an autoantibody that recognizes a skin basement membrane component.

L10 ANSWER 5 OF 65 USPATFULL
ACCESSION NUMBER: 2002:32228 USPATFULL
TITLE: Methods for enhancing the expression of a protein of interest by recombinant host cells
INVENTOR(S): Lok, Si, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019049	A1	20020214
APPLICATION INFO.:	US 2001-842746	A1	20010425 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-199760P	20000426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Phillip Jones, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:32228 USPATFULL
TI Methods for enhancing the expression of a protein of interest by recombinant host cells

IN Lok, Si, Seattle, WA, UNITED STATES
PI US 2002019049 A1 20020214
AI US 2001-842746 A1 20010425 (9)
PRAI US 2000-199760P 20000426 (60)
DT Utility
FS APPLICATION
LREP Phillip Jones, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The increased use of nucleotide sequence data mining techniques has amplified the demand for efficient methods of producing recombinant proteins in eukaryotic cells. A strategy is provided for enhancing the synthesis of recombinant amino acid sequences by polymerizing expression cassettes in vitro before producing recombinant hosts.

L10 ANSWER 6 OF 65 USPATFULL
ACCESSION NUMBER: 2002:12259 USPATFULL
TITLE: Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
INVENTOR(S): Better, Marc D., Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002006638	A1	20020117
APPLICATION INFO.:	US 2001-765527	A1	20010118 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-217352, filed on 21 Dec 1998, GRANTED, Pat. No. US 6274344
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Janet M. McNicholas, Ph. D., McAndrews, Held & Malloy, Ltd., 34th Floor, 500 West Madison Street, Chicago, IL, 60661
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 4350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:12259 USPATFULL
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
IN Better, Marc D., Los Angeles, CA, UNITED STATES
PI US 2002006638 A1 20020117
AI US 2001-765527 A1 20010118 (9)
RLI Continuation of Ser. No. US 1998-217352, filed on 21 Dec 1998, GRANTED, Pat. No. US 6274344
DT Utility
FS APPLICATION
LREP Janet M. McNicholas, Ph. D., McAndrews, Held & Malloy, Ltd., 34th Floor, 500 West Madison Street, Chicago, IL, 60661
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

L10 ANSWER 7 OF 65 USPATFULL

ACCESSION NUMBER:	2002:102627 USPATFULL
TITLE:	Sequence directed DNA binding molecules compositions and methods
INVENTOR(S):	Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Maynard, MA, United States Turin, Lisa M., Redwood City, CA, United States Fry, Kirk E., Palo Alto, CA, United States
PATENT ASSIGNEE(S):	Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6384208	B1	20020507
APPLICATION INFO.:	US 1999-354947		19990715 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Schwartzman, Robert A.
ASSISTANT EXAMINER:	Davis, Katharine F.
LEGAL REPRESENTATIVE:	Fabian, Gary, Thrower, Larry W., Perkins Coie LLP
NUMBER OF CLAIMS:	1
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	71 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT:	5215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	2002:102627 USPATFULL
TI	Sequence directed DNA binding molecules compositions and methods
IN	Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Maynard, MA, United States Turin, Lisa M., Redwood City, CA, United States Fry, Kirk E., Palo Alto, CA, United States
PA	Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI	US 6384208 B1 20020507
AI	US 1999-354947 19990715 (9)
RLI	Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT	Utility
FS	GRANTED
EXNAM	Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Davis, Katharine F.
LREP	Fabian, Gary, Thrower, Larry W., Perkins Coie LLP
CLMN	Number of Claims: 1
ECL	Exemplary Claim: 1

DRWN 71 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 5215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 8 OF 65 USPATFULL

ACCESSION NUMBER:	2002:75470 USPATFULL			
TITLE:	Dithiolane derivatives			
INVENTOR(S):	Pershadsingh, Harrihar A., Bakersfield, CA, United States Avery, Mitchell A., Oxford, MS, United States			
PATENT ASSIGNEE(S):	Bethesda Pharmaceuticals, Inc., Bakersfield, CA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6369098	B1	20020409	
APPLICATION INFO.:	US 2000-684738		20001004	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 1999-157890P		19991005	(60)
	US 2000-185347P		20000226	(60)
	US 2000-225907P		20000817	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Lambkin, Deborah C.			
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP			
NUMBER OF CLAIMS:	42			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 22 Drawing Page(s)			
LINE COUNT:	3404			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	2002:75470 USPATFULL		
TI	Dithiolane derivatives		
IN	Pershadsingh, Harrihar A., Bakersfield, CA, United States Avery, Mitchell A., Oxford, MS, United States		
PA	Bethesda Pharmaceuticals, Inc., Bakersfield, CA, United States (U.S. corporation)		
PI	US 6369098	B1	20020409
AI	US 2000-684738		20001004 (9)
PRAI	US 1999-157890P		19991005 (60)
	US 2000-185347P		20000226 (60)
	US 2000-225907P		20000817 (60)
DT	Utility		
FS	GRANTED		
EXNAM	Primary Examiner: Lambkin, Deborah C.		
LREP	Townsend and Townsend and Crew LLP		
CLMN	Number of Claims: 42		
ECL	Exemplary Claim: 1		
DRWN	22 Drawing Figure(s); 22 Drawing Page(s)		
LN.CNT	3404		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods for synthesizing novel dithiolane derivatives, ligands with high affinity for the nuclear hormone receptors, peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) and/or PPAR.alpha.. Methods for using these compounds in the treatment of endocrine, skin, cardiovascular, immunological, neurological, neuropsychiatric, neoplastic and chronic viral diseases of various organs, including the eye are described. Methods of treating proliferative and inflammatory diseases, degenerative diseases, and age-related dysregulations, caused by an hereditary (genetic) condition or an environmental insult are also provided. In addition, methods are provided for treating conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, a PPAR.alpha. agonist, and a second agent selected from the following: a PPAR.gamma. ligand, or an RXR ligand (rexinoid), or a PPAR.gamma./RXR ligand, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.

L10 ANSWER 9 OF 65 USPATFULL

ACCESSION NUMBER:	2002:63923 USPATFULL
TITLE:	Azole compounds, their production and use
INVENTOR(S):	Itoh, Katsumi, Osaka, JAPAN Okonogi, Kenji, Osaka, JAPAN Tasaka, Akihiro, Osaka, JAPAN
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362206	B1	20020326
APPLICATION INFO.:	US 1999-413876		19991007 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 624649, now patented, Pat. No. US 6034248		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-29579	19950217
	JP 1995-285318	19951101

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Morris, Patricia L.
LEGAL REPRESENTATIVE:	Foley & Lardner
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	2251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	2002:63923 USPATFULL
TI	Azole compounds, their production and use
IN	Itoh, Katsumi, Osaka, JAPAN Okonogi, Kenji, Osaka, JAPAN Tasaka, Akihiro, Osaka, JAPAN
PA	Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)
PI	US 6362206 B1 20020326
AI	US 1999-413876 19991007 (9)
RLI	Division of Ser. No. US 624649, now patented, Pat. No. US 6034248
PRAI	JP 1995-29579 19950217 JP 1995-285318 19951101
DT	Utility
FS	GRANTED
EXNAM	Primary Examiner: Morris, Patricia L.
LREP	Foley & Lardner
CLMN	Number of Claims: 11

ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an azole compound represented by the formula (I): ##STR1##

wherein Ar is an optionally substituted phenyl group; R.sup.1 and R.sup.2, the same or different, are a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to form a lower alkylene group; R is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; A is Y.dbd.Z (Y and Z, the same or different, are a nitrogen atom or a methine group optionally substituted with a lower alkyl group) or an ethylene group optionally substituted with a lower alkyl group; n is an integer from 0 to 2; and Az is an optionally substituted azolyl group, or its salt, which is useful for a prevention and therapy of a fungal infection of a mammal as a antifungal agent.

L10 ANSWER 10 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 2002:407170 SCISEARCH
THE GENUINE ARTICLE: 547ZQ
TITLE: Dermal application of jet fuel suppresses secondary immune reactions
AUTHOR: Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)
CORPORATE SOURCE: Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA
COUNTRY OF AUTHOR: USA
SOURCE: TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 2002:407170 SCISEARCH
GA The Genuine Article (R) Number: 547ZQ
TI Dermal application of jet fuel suppresses secondary immune reactions
AU Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)
CS Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA
CYA USA
SO TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.
DT Article; Journal
LA English
REC Reference Count: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Applying military jet fuel (JP-8) to the skin of mice activates systemic immune suppression. In all of our previous experiments, JP-8 was applied to immunologically naive mice. The effect of jet fuels on established immune reactions, such as immunological memory, is unknown. The focus of the experiments presented here was to test the hypothesis that jet fuel exposure [both JP-8 and commercial jet fuel (Jet-A)] suppresses established immune reactions. Mice were immunized with the

opportunistic fungal pathogen **Candida albicans** and, at different times after immunization (10 to 30 days), various doses of undiluted JP-8 or Jet-A were applied to their skin. Both the elicitation of delayed-type hypersensitivity (DTH) (mice challenged 10 days after immunization) and immunological memory (mice challenged 30 days after immunization) were significantly suppressed in a dose-dependent manner. Dermal exposure to either multiple small doses (50 mul over 4 days) or a single large dose (approximate to200-300 mul) of JP-8 and/or Jet-A suppressed DTH to C. **albicans**. The mechanism by which dermal application of JP-8 and Jet-A suppresses immunological memory involves the release of immune biologic response modifiers. Blocking the production of prostaglandin E, by a selective cyclooxygenase-2 inhibitor (SC 236) significantly reversed jet fuel-induced suppression of immunologic memory. These findings indicate, for the first time, that dermal exposure to commercial jet fuel (Jet-A) suppresses the immune response. In addition, the data reported here expand on previous findings by suggesting that jet fuel exposure may depress the protective effect of prior vaccination. (C) 2002 Elsevier Science (USA).

L10 ANSWER 11 OF 65 USPATFULL

ACCESSION NUMBER:	2001:145079 USPATFULL
TITLE:	Methods for the isolation of bacteria containing eukaryotic genes
INVENTOR(S):	Robinson, Douglas H., Washington, DC, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018214	A1	20010830
APPLICATION INFO.:	US 2001-759345	A1	20010116 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-382816, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US 1996-719367, filed on 25 Sep 1996, GRANTED, Pat. No. US 6022730 Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994, ABANDONED
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ROTHWELL, FIGG, ERNST & MANBECK, P.C., 555 13TH STREET, N.W., SUITE 701, EAST TOWER, WASHINGTON, DC, 20004
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
LINE COUNT:	974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	2001:145079 USPATFULL
TI	Methods for the isolation of bacteria containing eukaryotic genes
IN	Robinson, Douglas H., Washington, DC, United States
PI	US 2001018214 A1 20010830
AI	US 2001-759345 A1 20010116 (9)
RLI	Continuation of Ser. No. US 1999-382816, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US 1996-719367, filed on 25 Sep 1996, GRANTED, Pat. No. US 6022730 Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994, ABANDONED
DT	Utility
FS	APPLICATION
LREP	ROTHWELL, FIGG, ERNST & MANBECK, P.C., 555 13TH STREET, N.W., SUITE 701, EAST TOWER, WASHINGTON, DC, 20004
CLMN	Number of Claims: 25
ECL	Exemplary Claim: 1
DRWN	No Drawings
LN.CNT	974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bacteria containing eukaryotic and/or viral genes, and often having highly pleiomorphic morphology, are obtained by culturing virally-infected eukaryotic cells under aseptic, low oxygen conditions. The bacteria so produced express products encoded by the eukaryotic

genes. Analyses indicate that several isolates obtained from culturing retrovirally-infected human brain capillary endothelial cells express human-specific genes previously mapped to widely separated human chromosomes.

L10 ANSWER 12 OF 65 USPATFULL
ACCESSION NUMBER: 2001:133881 USPATFULL
TITLE: IMMUNIZATION AGAINST ENDOGENOUS MOLECULES
INVENTOR(S): HARLAND, RICHARD, SASKATOON, Canada
MANNS, JOHN G., SASKATOON, Canada
ACRES, STEPHEN D., SASKATOON, Canada

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014330	A1	20010816
APPLICATION INFO.:	US 1998-19010	A1	19980205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-36883P	19970205 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBINS & PASTERNAK LLP, 90 MIDDLEFIELD ROAD, SUITE 200, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:133881 USPATFULL
TI IMMUNIZATION AGAINST ENDOGENOUS MOLECULES
IN HARLAND, RICHARD, SASKATOON, Canada
MANNS, JOHN G., SASKATOON, Canada
ACRES, STEPHEN D., SASKATOON, Canada
PI US 2001014330 A1 20010816
AI US 1998-19010 A1 19980205 (9)
PRAI US 1997-36883P 19970205 (60)
DT Utility
FS APPLICATION
LREP ROBINS & PASTERNAK LLP, 90 MIDDLEFIELD ROAD, SUITE 200, MENLO PARK, CA, 94025
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is described for immunoneutralization of endogenous molecules in mammalian subjects, wherein an immunogen is administered via injection to the ear. The method is used to elicit an efficient and uniform immune response sufficient to block or suppress the activity of an endogenous hormone in a vaccinated subject, or to target a diseased cell for an immune response.

L10 ANSWER 13 OF 65 USPATFULL
ACCESSION NUMBER: 2001:235103 USPATFULL
TITLE: Method and product for regulating cell responsiveness to external signals
INVENTOR(S): Johnson, Gary L., Boulder, CO, United States
PATENT ASSIGNEE(S): National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333170	B1	20011225

APPLICATION INFO.: US 1996-628829 19960405 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-440421, filed on 12 May 1995, now abandoned Continuation-in-part of Ser. No. US 1994-323460, filed on 14 Oct 1994, now patented, Pat. No. US 5854043 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941 , said Ser. No. US 440421 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941 , said Ser. No. US 628829 Continuation-in-part of Ser. No. US 1995-410602, filed on 24 Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1995-472934, filed on 6 Jun 1995, now patented, Pat. No. US 5753446
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kemmerer, Elizabeth
ASSISTANT EXAMINER: Basi, Nirmal S.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Esq., Guilio A., Lauro, Esq., Peter C.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 30 Drawing Page(s)
LINE COUNT: 6027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:235103 USPATFULL
TI Method and product for regulating cell responsiveness to external signals
IN Johnson, Gary L., Boulder, CO, United States
PA National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)
PI US 6333170 B1 20011225
AI US 1996-628829 19960405 (8)
RLI Continuation-in-part of Ser. No. US 1995-440421, filed on 12 May 1995, now abandoned Continuation-in-part of Ser. No. US 1994-323460, filed on 14 Oct 1994, now patented, Pat. No. US 5854043 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941 , said Ser. No. US 440421 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941 , said Ser. No. US 628829 Continuation-in-part of Ser. No. US 1995-410602, filed on 24 Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1995-472934, filed on 6 Jun 1995, now patented, Pat. No. US 5753446
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kemmerer, Elizabeth; Assistant Examiner: Basi, Nirmal S.
LREP Lahive & Cockfield, LLP, DeConti, Jr., Esq., Guilio A., Lauro, Esq., Peter C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 6027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate signal transduction in a cell. The present invention also includes therapeutic compositions comprising such proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MKKs 1-4 (also referred to as MEK-1, MEK-2 and JNKK1 and JNKK2).

L10 ANSWER 14 OF 65 USPATFULL
ACCESSION NUMBER: 2001:231160 USPATFULL
TITLE: Secreted salivary ZSIG63 Polypeptide
INVENTOR(S): Adler, David A., Bainbridge Island, WA, United States
Sheppard, Paul O., Granite Falls, WA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331413	B1	20011218
APPLICATION INFO.:	US 2000-527345		20000317 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124820P	19990317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Monshipouri, Maryam
LEGAL REPRESENTATIVE: Johnson, JD, Jennifer K.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 2896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:231160 USPATFULL
TI Secreted salivary ZSIG63 Polypeptide
IN Adler, David A., Bainbridge Island, WA, United States
Sheppard, Paul O., Granite Falls, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6331413 B1 20011218
AI US 2000-527345 20000317 (9)
PRAI US 1999-124820P 19990317 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Monshipouri, Maryam
LREP Johnson, JD, Jennifer K.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to polynucleotide and polypeptide molecules for zsig63, a novel secreted salivary protein. The polypeptides, and polynucleotides encoding them, may exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The polynucleotides encoding zsig63, are located on chromosome 4, and can be used to identify a region of the genome associated with human disease states. The present invention also includes antibodies to the zsig63 polypeptides.

L10 ANSWER 15 OF 65 USPATFULL
ACCESSION NUMBER: 2001:208983 USPATFULL
TITLE: Adrenomedullin peptides
INVENTOR(S): Cutitta, Frank, Adamstown, MD, United States
Martinez, Alfredo, Washington, DC, United States
Miller, Mae Jean, Monrovia, MD, United States
Unsworth, Edward J., Kensington, MD, United States
Hook, William, Wheaton, MD, United States
Walsh, Thomas, Bethesda, MD, United States
Gray, Karen, Gaithersburg, MD, United States
Macri, Charles, Kensington, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the

Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6320022	B1	20011120	
	WO 9707214		19970227	
APPLICATION INFO.:	US 1998-11922		19980217	(9)
	WO 1996-US13286		19960816	
			19980217	PCT 371 date
			19980217	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13172P	19960312 (60)
	US 1995-2936P	19950830 (60)
	US 1995-2514P	19950818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ungar, Susan
LEGAL REPRESENTATIVE: Morgan & Finnegan, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 76 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 2185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:208983 USPATFULL
TI Adrenomedullin peptides
IN Cutitta, Frank, Adamstown, MD, United States
Martinez, Alfredo, Washington, DC, United States
Miller, Mae Jean, Monrovia, MD, United States
Unsworth, Edward J., Kensington, MD, United States
Hook, William, Wheaton, MD, United States
Walsh, Thomas, Bethesda, MD, United States
Gray, Karen, Gaithersburg, MD, United States
Macri, Charles, Kensington, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6320022 B1 20011120
WO 9707214 19970227
AI US 1998-11922 19980217 (9)
WO 1996-US13286 19960816
19980217 PCT 371 date
19980217 PCT 102(e) date
PRAI US 1996-13172P 19960312 (60)
US 1995-2936P 19950830 (60)
US 1995-2514P 19950818 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ungar, Susan
LREP Morgan & Finnegan, LLP
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 76 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 2185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The

methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.

L10 . ANSWER 16 OF 65 USPATFULL
ACCESSION NUMBER: 2001:157795 USPATFULL
TITLE: Anti-IgE antibodies and method of improving polypeptides
INVENTOR(S): Lowman, Henry B., 400 San Juan Ave., El Granada, CA, United States 94018
Presta, Leonard G., 1900 Gough St. #206, San Francisco, CA, United States 94109
Jardieu, Paula M., 33 Hayward Ave. #110, San Mateo, CA, United States 94401-4319
Lowe, John, 396 Michelle La., Daly City, CA, United States 94080

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6290957	B1	20010918
APPLICATION INFO.:	US 1999-296005		19990421 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, now patented, Pat. No. US 5994511
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:157795 USPATFULL
TI Anti-IgE antibodies and method of improving polypeptides
IN Lowman, Henry B., 400 San Juan Ave., El Granada, CA, United States 94018
Presta, Leonard G., 1900 Gough St. #206, San Francisco, CA, United States 94109
Jardieu, Paula M., 33 Hayward Ave. #110, San Mateo, CA, United States 94401-4319
Lowe, John, 396 Michelle La., Daly City, CA, United States 94080
PI US 6290957 B1 20010918
AI US 1999-296005 19990421 (9)
RLI Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, now patented, Pat. No. US 5994511
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saunders, David
LREP Svoboda, Craig G.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 4910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for adjusting the affuinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues

is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 17 OF 65 USPATFULL
ACCESSION NUMBER: 2001:131064 USPATFULL
TITLE: Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
INVENTOR(S): Better, Marc D., Los Angeles, CA, United States
PATENT ASSIGNEE(S): XOMA Corporation, Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274344	B1	20010814
APPLICATION INFO.:	US 1998-217352		19981221 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-621803, filed on 22 Mar 1996, now patented, Pat. No. US 5851802
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Robinson, Patricia
LEGAL REPRESENTATIVE: McAndrews, Held & Malloy, Ltd.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:131064 USPATFULL
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
IN Better, Marc D., Los Angeles, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 6274344 B1 20010814
AI US 1998-217352 19981221 (9)
RLI Continuation of Ser. No. US 1996-621803, filed on 22 Mar 1996, now patented, Pat. No. US 5851802
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Patricia
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

L10 ANSWER 18 OF 65 USPATFULL
ACCESSION NUMBER: 2001:125966 USPATFULL
TITLE: Reduction of impairment of respiratory tract mucosal immunity
INVENTOR(S): Kudsk, Kenneth A., Memphis, TN, United States
PATENT ASSIGNEE(S): University of Tennessee Research Corporation, Knoxville, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 6271202	B1	20010807
APPLICATION INFO.:	US 1998-67032		19980428 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-842877, filed on 17 Apr 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-15835P	19960419 (60)
	US 1996-29689P	19961031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:125966 USPATFULL
TI Reduction of impairment of respiratory tract mucosal immunity
IN Kudsk, Kenneth A., Memphis, TN, United States
PA University of Tennessee Research Corporation, Knoxville, TN, United States (U.S. corporation)
PI US 6271202 B1 20010807
AI US 1998-67032 19980428 (9)
RLI Continuation-in-part of Ser. No. US 1997-842877, filed on 17 Apr 1997, now abandoned
PRAI US 1996-15835P 19960419 (60)
US 1996-29689P 19961031 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods for reducing the impairment respiratory tract mucosal immunity associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. Also described are methods for reducing the rate of infection of the respiratory tract by pathogenic microorganisms associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. In addition, a method of reducing the atrophy or dysfunction of the GALT comprising administering a therapeutically effective amount of a neuropeptide is described. The specification further describes compositions for reducing or preventing the impairment of intestinal or respiratory tract mucosal immunity comprising a neuropeptide and a pharmaceutically acceptable carrier.

L10 ANSWER 19 OF 65 USPATFULL
ACCESSION NUMBER: 2001:112293 USPATFULL
TITLE: Reduction of impairment of respiratory tract mucosal immunity
INVENTOR(S): Kudsk, Kenneth A., Memphis, TN, United States
PATENT ASSIGNEE(S): University of Tennessee Research Corporation, Memphis, TN, United States (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION:	US 6262027	B1	20010717
APPLICATION INFO.:	US 1999-473355		19991228 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-67032, filed on 28 Apr 1998 Continuation-in-part of Ser. No. US 1997-842877, filed on 17 Apr 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-15835P	19960419 (60)
	US 1996-29689P	19961031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:112293 USPATFULL
TI Reduction of impairment of respiratory tract mucosal immunity
IN Kudsk, Kenneth A., Memphis, TN, United States
PA University of Tennessee Research Corporation, Memphis, TN, United States (U.S. corporation)
PI US 6262027 B1 20010717
AI US 1999-473355 19991228 (9)
RLI Division of Ser. No. US 1998-67032, filed on 28 Apr 1998 Continuation-in-part of Ser. No. US 1997-842877, filed on 17 Apr 1997, now abandoned
PRAI US 1996-15835P 19960419 (60)
US 1996-29689P 19961031 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes methods for reducing the impairment respiratory tract mucosal immunity associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. Also described are methods for reducing the rate of infection of the respiratory tract by pathogenic microorganisms associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. In addition, a method of reducing the atrophy or dysfunction of the GALT comprising administering a therapeutically effective amount of a neuropeptide is described. The specification further describes compositions for reducing or preventing the impairment of intestinal or respiratory tract mucosal immunity comprising a neuropeptide and a pharmaceutically acceptable carrier.

L10 ANSWER 20 OF 65 USPATFULL
ACCESSION NUMBER: 2001:82521 USPATFULL
TITLE: Methods for determining binding of an analyte to a receptor
INVENTOR(S): Idusogie, Esohe Ekinaduese, Burlingame, CA, United States
Mulkerrin, Michael George, Hillsborough, CA, United States

Presta, Leonard G., San Francisco, CA, United States
Shields, Robert Laird, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6242195	B1	20010605
APPLICATION INFO.:	US 1998-54255		19980402 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brumback, Brenda
ASSISTANT EXAMINER: Nichols, Jennifer
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:82521 USPATFULL
TI Methods for determining binding of an analyte to a receptor
IN Idusogie, Esohe Ekinaduese, Burlingame, CA, United States
Mulkerrin, Michael George, Hillsborough, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Shields, Robert Laird, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6242195 B1 20010605
AI US 1998-54255 19980402 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Brumback, Brenda; Assistant Examiner: Nichols, Jennifer
LREP Lee, Wendy M.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.

L10 ANSWER 21 OF 65 USPATFULL
ACCESSION NUMBER: 2001:29701 USPATFULL
TITLE: Polypeptide variants
INVENTOR(S): Idusogie, Esohe Ekinaduese, Burlingame, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Mulkerrin, Michael George, Hillsborough, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6194551	B1	20010227
APPLICATION INFO.:	US 1999-282505		19990331 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80447P	19980402 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: DiBrino, Marianne
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2593
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:29701 USPATFULL
TI Polypeptide variants
IN Idusogie, Esohe Ekinaduese, Burlingame, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Mulkerrin, Michael George, Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6194551 B1 20010227
AI US 1999-282505 19990331 (9)
PRAI US 1998-80447P 19980402 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: DiBrino, Marianne
LREP Lee, Wendy M.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2593
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.

L10 ANSWER 22 OF 65 USPATFULL
ACCESSION NUMBER: 2001:14522 USPATFULL
TITLE: Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock
INVENTOR(S): Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria Ornella, Rome, Italy
Scafetta, Nazareno, Pavona di Albano, Italy
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6180667	B1	20010130
APPLICATION INFO.:	US 1997-827448		19970328 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-274686, filed on 14 Jul 1994, now patented, Pat. No. US 5625085

	NUMBER	DATE

PRIORITY INFORMATION:	IT 1993-RM468	19930714
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shippen, Michael L.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	967	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:14522 USPATFULL

TI Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock

IN Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria Ornella, Rome, Italy
Scafetta, Nazareno, Pavona di Albano, Italy

PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)

PI US 6180667 B1 20010130

AI US 1997-827448 19970328 (8)

RLI Division of Ser. No. US 1994-274686, filed on 14 Jul 1994, now patented, Pat. No. US 5625085

PRAI IT 1993-RM468 19930714

DT Utility

FS Granted

EXNAM Primary Examiner: Shippen, Michael L.

LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 967

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, staight or branched alkanoyl having 2-26 carbon atoms, optionally .omega.-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

L10 ANSWER 23 OF 65 USPATFULL

ACCESSION NUMBER:	2001:4887 USPATFULL	
TITLE:	Anti-IgE antibodies and method of improving polypeptides	
INVENTOR(S):	Lowman, Henry B., El Granada, CA, United States Presta, Leonard G., San Francisco, CA, United States Jardieu, Paula M., San Mateo, CA, United States Lowe, John, Daly City, CA, United States	
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172213	B1	20010109
APPLICATION INFO.:	US 1998-109207		19980630 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51554P	19970702 (60)
DOCUMENT TYPE:	Patent	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Christina Y.	
ASSISTANT EXAMINER:	Ewoldt, Gerald R.	

LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:4887 USPATFULL
TI Anti-IgE antibodies and method of improving polypeptides
IN Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6172213 B1 20010109
AI US 1998-109207 19980630 (9)
PRAI US 1997-51554P 19970702 (60)
DT Patent
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Ewoldt, Gerald R.
LREP Svoboda, Craig G.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 4829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 24 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 2001:896861 SCISEARCH
THE GENUINE ARTICLE: 488ZW
TITLE: Induction of histamine release from rat peritoneal mast cells by histatins
AUTHOR: Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K
CORPORATE SOURCE: Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan
COUNTRY OF AUTHOR: Japan
SOURCE: BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.
Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.
ISSN: 0918-6158.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 2001:896861 SCISEARCH
GA The Genuine Article (R) Number: 488ZW
TI Induction of histamine release from rat peritoneal mast cells by histatins
AU Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K
CS Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan
CYA Japan
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.
Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.
ISSN: 0918-6158.
DT Article; Journal
LA English
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Human salivary histatins (Hsts), which belong to a salivary polypeptide family, have potent antifungal activity against **Candida albicans** and Cryptococcus neoformans, and are expected to be useful as therapeutic reagents against **Candida** species. However, little is known about the effect of Hsts on host immune systems. Thus we conducted a series of in vitro experiments with rat mast cells to determine whether histatin 5 (Hst 5) or histatin 8 (Hst 8) has a histamine-releasing effect on mast cells. Both Hst 5 and Hst 8 induced histamine release from rat peritoneal mast cells in a dose-dependent manner (10(-9) to 10(-5) m). Hst 5 had a stronger releasing effect than Hst 8. The histamine release induced by Hst 5 (10(-6) M) was increased by the presence of 0.5 mm Ca2+, but decreased by 2 mm Ca2+. Alternatively, the histamine release induced by Hst 8 (10(-6) M) was inhibited by the presence of Ca2+ (0.5 to 2 mm). These results suggest that Hsts have limited usefulness as therapeutic agents due to induction of histamine release from mast cells.

L10 ANSWER 25 OF 65 USPATFULL
ACCESSION NUMBER: 2000:160615 USPATFULL
TITLE: Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
INVENTOR(S): Jin, Tuo, Newark, NJ, United States
Zarif, Leila, Newark, NJ, United States
Mannino, Raphael, Annandale, NJ, United States
PATENT ASSIGNEE(S): Biodelivery Sciences, Inc., Newark, NJ, United States (U.S. corporation)
University of Medicine and Denistry of New Jersey, Newark, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153217		20001128
APPLICATION INFO.:	US 1999-235400		19990122 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:160615 USPATFULL
TI Nanocochleate formulations, process of preparation and method of

delivery of pharmaceutical agents
IN Jin, Tuo, Newark, NJ, United States
Zarif, Leila, Newark, NJ, United States
Mannino, Raphael, Annandale, NJ, United States
PA Biodelivery Sciences, Inc., Newark, NJ, United States (U.S. corporation)
University of Medicine and Denistry of New Jersey, Newark, NJ, United States (U.S. corporation)
PI US 6153217 20001128
AI US 1999-235400 19990122 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing a small-sized, lipid-based cochleate is described. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structure by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca.sup.2+ or Zn.sup.2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing pharmaceutical agents or biologically relevant molecules. Small-sized cochleates may be administered orally or through the mucosa to obtain an effective method of treatment.

L10 ANSWER 26 OF 65 USPATFULL
ACCESSION NUMBER: 2000:121617 USPATFULL
TITLE: Libraries of backbone-cyclized peptidomimetics
INVENTOR(S): Gilon, Chaim, Jerusalem, Israel
Hornik, Vered, Rehovot, Israel
PATENT ASSIGNEE(S): Peptor Limited, Rehovot, Israel (non-U.S. corporation)
Yissum Research Development Company of The Hebrew University in Jerusalem, Jerusalem, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117974		20000912
APPLICATION INFO.:	US 1995-569042		19951207 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-444135, filed on 18 May 1995, now patented, Pat. No. US 5723575 which is a continuation-in-part of Ser. No. US 1992-955380, filed on 1 Oct 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-99628	19911002
	IL 1995-115096	19950829

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Celsa, Bennett
ASSISTANT EXAMINER: Ricigliamo, Joseph W.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 2150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:121617 USPATFULL
TI Libraries of backbone-cyclized peptidomimetics

IN Gilon, Chaim, Jerusalem, Israel
Hornik, Vered, Rehovot, Israel
PA Peptor Limited, Rehovot, Israel (non-U.S. corporation)
Yissum Research Development Company of The Hebrew University in Jerusalem, Jerusalem, Israel (non-U.S. corporation)
PI US 6117974 20000912
AI US 1995-569042 19951207 (8)
RLI Continuation-in-part of Ser. No. US 1995-444135, filed on 18 May 1995, now patented, Pat. No. US 5723575 which is a continuation-in-part of Ser. No. US 1992-955380, filed on 1 Oct 1992, now abandoned
PRAI IL 1991-99628 19911002
IL 1995-115096 19950829
DT Utility
FS Granted
EXNAM Primary Examiner: Celsa, Bennett; Assistant Examiner: Ricigliamo, Joseph W.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Libraries of novel backbone-cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units used in the synthesis of these backbone-cyclized peptide analogs are N(((-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N(((-functionalized) amino acids are incorporated into a library of peptide sequences, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by libraries of backbone-cyclized bradykinin analogs, somatostatin analogs, BPI analogs and **Substance P** analogs having biological activity. Further embodiments of the invention are Interleukin-6 receptor derived peptides having ring structures involving backbone cyclization.

L10 ANSWER 27 OF 65 USPATFULL
ACCESSION NUMBER: 2000:117288 USPATFULL
TITLE: Pharmaceutical grade St. John's Wort
INVENTOR(S): Khwaja, Tasneem A., Corona Del Mar, CA, United States
Friedman, Elliot P., Montecito, CA, United States
PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)
Pharmaprint Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6113907		20000905
APPLICATION INFO.:	US 1997-956602		19971023 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-838198, filed on 15 Apr 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gitomer, Ralph
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 3067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:117288 USPATFULL
TI Pharmaceutical grade St. John's Wort
IN Khwaja, Tasneem A., Corona Del Mar, CA, United States
Friedman, Elliot P., Montecito, CA, United States
PA University of Southern California, Los Angeles, CA, United States (U.S. corporation)
Pharmaprint Inc., Irvine, CA, United States (U.S. corporation)
PI US 6113907 20000905
AI US 1997-956602 19971023 (8)
RLI Continuation-in-part of Ser. No. US 1997-838198, filed on 15 Apr 1997, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Gitomer, Ralph
LREP Lyon & Lyon LLP
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 3067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to St. John's Wort materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. More particularly, the present invention relates to the use of compositional and activity fingerprints in the processing of St. John's Wort materials to produce drugs which qualify as pharmaceutical grade compositions which are suitable for use in clinical or veterinary settings to treat and/or ameliorate diseases, disorders or conditions.

L10 ANSWER 28 OF 65 USPATFULL

ACCESSION NUMBER:	2000:98190 USPATFULL		
TITLE:	Noncloning technique for expressing a gene of interest		
INVENTOR(S):	Selby, Mark, San Francisco, CA, United States Thudium, Kent B., Oakland, CA, United States Dina, Dino, Oakland, CA, United States		
PATENT ASSIGNEE(S):	Chiron Corporation, Emeryville, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096505		20000801
APPLICATION INFO.:	US 1999-290449		19990413 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1998-81777P		19980414 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
ASSISTANT EXAMINER:	Sandals, William		
LEGAL REPRESENTATIVE:	Robins, Roberta L., Harbin, Alisa A., Blackburn, Robert P.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1328		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:98190 USPATFULL
TI Noncloning technique for expressing a gene of interest
IN Selby, Mark, San Francisco, CA, United States
Thudium, Kent B., Oakland, CA, United States
Dina, Dino, Oakland, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 6096505 20000801

AI US 1999-290449 19990413 (9)
PRAI US 1998-81777P 19980414 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Sandals, William
LREP Robins, Roberta L., Harbin, Alisa A., Blackburn, Robert P.
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A noncloning method for expressing a gene of interest in a mammalian host cell is disclosed. The invention utilizes three basic individual elements: (1) a promoter element; (2) at least one gene of interest; and (3) a selectable marker cassette which includes in 5' to 3' order, an internal ribosome entry site ("IRES"), at least one gene coding for a selectable marker, and a transcription termination sequence. The three individual elements are cotransfected into a mammalian host cell where they become operably linked such that expression of the selectable marker gene(s) necessarily requires coexpression of the gene of interest.

L10 ANSWER 29 OF 65 USPATFULL
ACCESSION NUMBER: 2000:41003 USPATFULL
TITLE: Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
INVENTOR(S): Ariizumi, Kiyoshi, Dallas, TX, United States
Takashima, Akira, Irving, TX, United States
PATENT ASSIGNEE(S): Board of Regents The University of Texas Systems, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046158		20000404
APPLICATION INFO.:	US 1996-772440		19961220 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Johnson, Nancy A
LEGAL REPRESENTATIVE: Arnold White & Durkee
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,2
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 6533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:41003 USPATFULL
TI Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
IN Ariizumi, Kiyoshi, Dallas, TX, United States
Takashima, Akira, Irving, TX, United States
PA Board of Regents The University of Texas Systems, Austin, TX, United States (U.S. corporation)
PI US 6046158 20000404
AI US 1996-772440 19961220 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Johnson, Nancy A
LREP Arnold White & Durkee
CLMN Number of Claims: 16
ECL Exemplary Claim: 1,2
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 6533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel genes expressed selectively by long-term dendritic cell (DC) lines

(XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a C-terminal extracellular domain that exhibits significant homology to the carbohydrate recognition domains (CRD) of C-type lectins. Expression of both genes is highly restricted to cells of DC lineage (including epidermal LC). Thus, these genes encode new, DC-specific members of the C-type lectin family, now termed "DC-associated C-type lectin-1 and -2" (dectin-1 and dectin-2). Two isoforms of the dectin-1 molecule and five isoforms of the dectin-2 molecule have also been identified. The invention further provides His-tagged fusion proteins comprising 6.times. histidine and the extracellular domain of dectin-1 or dectin-2. Also provided are antibodies raised to synthetic peptides designed from the dectin-1 sequence or to the His-tagged fusion proteins described.

L10 ANSWER 30 OF 65 USPATFULL

ACCESSION NUMBER:	2000:28143 USPATFULL			
TITLE:	Azole compounds, their production and use			
INVENTOR(S):	Itoh, Katsumi, Osaka, Japan Okonogi, Kenji, Osaka, Japan Tasaka, Akihiro, Osaka, Japan			
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6034248		20000307	
	WO 9625410		19960820	
APPLICATION INFO.:	US 1996-624649		19961017	(8)
	WO 1996-JP325		19960215	
			19961017	PCT 371 date
			19961017	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1995-29579		19950217	
	JP 1995-285318		19951101	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Morris, Patricia L.			
LEGAL REPRESENTATIVE:	Foley & Lardner			
NUMBER OF CLAIMS:	7			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2340			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	2000:28143 USPATFULL		
TI	Azole compounds, their production and use		
IN	Itoh, Katsumi, Osaka, Japan		
	Okonogi, Kenji, Osaka, Japan		
	Tasaka, Akihiro, Osaka, Japan		
PA	Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)		
PI	US 6034248	20000307	
	WO 9625410 19960820		
AI	US 1996-624649	19961017	(8)
	WO 1996-JP325	19960215	
		19961017	PCT 371 date
		19961017	PCT 102(e) date
PRAI	JP 1995-29579	19950217	
	JP 1995-285318	19951101	
DT	Utility		
FS	Granted		
EXNAM	Primary Examiner: Morris, Patricia L.		

LREP Foley & Lardner
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2340
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an azole compound represented by the formula (I): ##STR1## wherein Ar is an optionally substituted phenyl group; R.sup.1 and R.sup.2, the same or different, are a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to form a lower alkylene group; R.sup.3 is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; A is Y.dbd.Z (Y and Z, the same or different, are a nitrogen atom or a methine group optionally substituted with a lower alkyl group) or an ethylene group optionally substituted with a lower alkyl group; n is an integer from 0 to 2; and Az is an optionally substituted azolyl group, or its salt, which is useful for a prevention and therapy of a fungal infection of a mammal as a antifungal agent.

L10 ANSWER 31 OF 65 USPATFULL
ACCESSION NUMBER: 2000:15506 USPATFULL
TITLE: Methods for the isolation of bacteria containing eukaryotic genes
INVENTOR(S): Robinson, Douglas H., 2301 N St., NW., Apt. 507, Washington, DC, United States 20037

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6022730		20000208
APPLICATION INFO.:	US 1996-719367		19960925 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Chris
ASSISTANT EXAMINER: Zeman, Manyk
LEGAL REPRESENTATIVE: Rothwell, Figg, Ernst & Kurz, p.c.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:15506 USPATFULL
TI Methods for the isolation of bacteria containing eukaryotic genes
IN Robinson, Douglas H., 2301 N St., NW., Apt. 507, Washington, DC, United States 20037
PI US 6022730 20000208
AI US 1996-719367 19960925 (8)
RLI Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994
DT Utility
FS Granted
EXNAM Primary Examiner: Eisenschenk, Chris; Assistant Examiner: Zeman, Manyk
LREP Rothwell, Figg, Ernst & Kurz, p.c.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Bacteria containing eukaryotic and/or viral genes, and often having highly pleiomorphic morphology, are obtained by culturing virally-infected eukaryotic cells under aseptic, low oxygen conditions. The bacteria so produced express products encoded by the eukaryotic genes. Analyses indicate that several isolates obtained from culturing retrovirally-infected human brain capillary endothelial cells express human-specific genes previously mapped to widely separated human

chromosomes.

L10 ANSWER 32 OF 65 USPATFULL

ACCESSION NUMBER:	2000:1692 USPATFULL
TITLE:	Sequence-directed DNA binding molecules compositions and methods
INVENTOR(S):	Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Maynard, MA, United States Turin, Lisa M., Redwood City, CA, United States Fry, Kirk E., Palo Alto, CA, United States
PATENT ASSIGNEE(S):	Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6010849		20000104
APPLICATION INFO.:	US 1995-482080		19950607 (8)

RELATED APPLN. INFO.:	Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Degen, Nancy
ASSISTANT EXAMINER:	Schwartzman, Robert
LEGAL REPRESENTATIVE:	Fabin, Gary R.Dehlinger & Associates
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT:	10022

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	2000:1692 USPATFULL
TI	Sequence-directed DNA binding molecules compositions and methods
IN	Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Maynard, MA, United States Turin, Lisa M., Redwood City, CA, United States Fry, Kirk E., Palo Alto, CA, United States
PA	Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)
PI	US 6010849 20000104
AI	US 1995-482080 19950607 (8)
RLI	Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT	Utility
FS	Granted
EXNAM	Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert
LREP	Fabin, Gary R.Dehlinger & Associates
CLMN	Number of Claims: 11
ECL	Exemplary Claim: 1
DRWN	48 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT	10022

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA:protein-binding assay useful for

screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 33 OF 65 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:216943 CAPLUS
DOCUMENT NUMBER: 130:236482
TITLE: Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and detection of TABM in disease states
INVENTOR(S): Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9914243	A1	19990325	WO 1998-AU765	19980916
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9890558	A1	19990405	AU 1998-90558	19980916

PRIORITY APPLN. INFO.:		
US 1997-59047P	P	19970916
AU 1998-5850	A	19980911
WO 1998-AU765	W	19980916

AN 1999:216943 CAPLUS
DN 130:236482
TI Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and detection of TABM in disease states
IN Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes
PA USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914243	A1	19990325	WO 1998-AU765	19980916
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9890558 A1 19990405 AU 1998-90558 19980916

PRAI US 1997-59047P P 19970916
AU 1998-5850 A 19980911
WO 1998-AU765 W 19980916

AB The present invention relates generally to immunointeractive mols. and their in the detection and/or purifn. of T-cell antigen binding mols. (TABMs). In a specific example, the authors disclose the prepn. and characterization of a monoclonal antibody to TABM. In a second example, transforming growth factor-.beta. is shown to bind TABM and to be activated on TABM binding to its cognate antigen. The ability to det. the presence and levels of particular TABMs may provide useful diagnostic procedures for a variety of disease conditions.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 34 OF 65 USPATFULL

ACCESSION NUMBER: 1999:155894 USPATFULL
TITLE: Anti-IgE antibodies and methods of improving polypeptides
INVENTOR(S): Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5994511		19991130	
APPLICATION INFO.:	US 1997-887352		19970702	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 5816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:155894 USPATFULL
TI Anti-IgE antibodies and methods of improving polypeptides
IN Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5994511 19991130
AI US 1997-887352 19970702 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Saunders, David
LREP Svoboda, Craig G.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 5816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and

screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 35 OF 65 USPATFULL

ACCESSION NUMBER:	1999:18912 USPATFULL
TITLE:	Method of determining DNA sequence preference of a DNA-binding molecule
INVENTOR(S):	Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Maynard, MA, United States Turin, Lisa M., Redwood City, CA, United States Fry, Kirk E., Palo Alto, CA, United States
PATENT ASSIGNEE(S):	Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869241		19990209
APPLICATION INFO.:	US 1995-475228		19950607 (8)

RELATED APPLN. INFO.:	Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Zitomer, Stepanie W.
ASSISTANT EXAMINER:	Whisenant, Ethan
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	72 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT:	9840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	1999:18912 USPATFULL
TI	Method of determining DNA sequence preference of a DNA-binding molecule
IN	Edwards, Cynthia A., Menlo Park, CA, United States Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Maynard, MA, United States Turin, Lisa M., Redwood City, CA, United States Fry, Kirk E., Palo Alto, CA, United States
PA	Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI	US 5869241 19990209
AI	US 1995-475228 19950607 (8)
RLI	Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT	Utility
FS	Granted
EXNAM	Primary Examiner: Zitomer, Stepanie W.; Assistant Examiner: Whisenant,

Ethan
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 9840
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 36 OF 65 USPATFULL
ACCESSION NUMBER: 1998:159736 USPATFULL
TITLE: Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
INVENTOR(S): Better, Marc D., Los Angeles, CA, United States
PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5851802		19981222
APPLICATION INFO.:	US 1996-621803		19960322 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
LEGAL REPRESENTATIVE: McAndrews, Held & Malloy, Ltd.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 4280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:159736 USPATFULL
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
IN Better, Marc D., Los Angeles, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5851802 19981222
AI US 1996-621803 19960322 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Spector, Lorraine
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 4280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

L10 ANSWER 37 OF 65 USPATFULL
ACCESSION NUMBER: 1998:124655 USPATFULL
TITLE: Method for making heteromultimeric polypeptides
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5821333		19981013
APPLICATION INFO.:	US 1995-434869		19950503 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Bakalyar, Heather A.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:124655 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5821333 19981013
AI US 1995-434869 19950503 (8)
RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bakalyar, Heather A.
LREP Lee, Wendy M.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

L10 ANSWER 38 OF 65 USPATFULL
ACCESSION NUMBER: 1998:111793 USPATFULL

TITLE: Method for making heteromultimeric polypeptides
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5807706		19980915
APPLICATION INFO.:	US 1995-433105		19950503 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Bakalyar, Heather A.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:111793 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5807706 19980915
AI US 1995-433105 19950503 (8)
RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bakalyar, Heather A.
LREP Lee, Wendy M.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

L10 ANSWER 39 OF 65 USPATFULL
ACCESSION NUMBER: 1998:44877 USPATFULL
TITLE: Sequence-directed DNA-binding molecules compositions and methods

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744131		19980428
APPLICATION INFO.:	US 1995-476876		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Atzel, Amy
LEGAL REPRESENTATIVE: Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 5113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:44877 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5744131 19980428
AI US 1995-476876 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 5113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 40 OF 65 USPATFULL
ACCESSION NUMBER: 1998:39383 USPATFULL

TITLE: Sequence-directed DNA-binding molecules compositions and methods

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5738990		19980414
APPLICATION INFO.:	US 1995-475221		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Guzo, David
ASSISTANT EXAMINER: Brusca, John S.
LEGAL REPRESENTATIVE: Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 5040

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:39383 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5738990 19980414
AI US 1995-475221 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David; Assistant Examiner: Brusca, John S.
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 5040

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 41 OF 65 USPATFULL
ACCESSION NUMBER: 1998:30879 USPATFULL
TITLE: Method for making heteromultimeric polypeptides
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5731168		19980324
APPLICATION INFO.:	US 1995-399106		19950301 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Bakalyar, Heather A.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:30879 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5731168 19980324
AI US 1995-399106 19950301 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bakalyar, Heather A.
LREP Lee, Wendy M.
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

L10 ANSWER 42 OF 65 USPATFULL
ACCESSION NUMBER: 1998:25075 USPATFULL
TITLE: Screening assay for the detection of DNA-binding molecules
INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States

	Cantor, Charles R., Boston, MA, United States Andrews, Beth M., Watertown, MA, United States Turin, Lisa M., Berkeley, CA, United States
PATENT ASSIGNEE(S):	Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5726014		19980310
APPLICATION INFO.:	US 1993-123936		19930917 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Atzel, Amy
LEGAL REPRESENTATIVE: Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 72 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT: 5659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:25075 USPATFULL
TI Screening assay for the detection of DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
Turin, Lisa M., Berkeley, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5726014 19980310
AI US 1993-123936 19930917 (8)
RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 5659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 43 OF 65 USPATFULL

ACCESSION NUMBER:	1998:14634 USPATFULL
TITLE:	Method of constructing sequence-specific DNA-binding molecules

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716780		19980210
APPLICATION INFO.:	US 1995-484499		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Atzel, Amy
LEGAL REPRESENTATIVE: Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 4929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:14634 USPATFULL
TI Method of constructing sequence-specific DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5716780 19980210
AI US 1995-484499 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 4929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 44 OF 65 USPATFULL
ACCESSION NUMBER: 97:112300 USPATFULL

TITLE: Method of ordering sequence binding preferences of a DNA-binding molecule

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States(4)
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693463		19971202
APPLICATION INFO.:	US 1992-996783		19921223 (7)

DISCLAIMER DATE: 20110426
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Atzel, Amy
LEGAL REPRESENTATIVE: Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 4908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:112300 USPATFULL
TI Method of ordering sequence binding preferences of a DNA-binding molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States4)
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5693463 19971202
AI US 1992-996783 19921223 (7)
DCD 20110426
RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 4908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 45 OF 65 USPATFULL
ACCESSION NUMBER: 97:86278 USPATFULL
TITLE: Preservatives and their use
INVENTOR(S): Eggensperger, Heinz, Hamburg, Germany, Federal Republic of
Diehl, Karl-Heinz, Norderstedt, Germany, Federal Republic of
Oltmanns, Peter, Hamburg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Schulke & Mayr GmbH, Hamburg, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670160		19970923
APPLICATION INFO.:	US 1996-649254		19960130 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-115298, filed on 1 Sep 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-741008, filed on 6 Aug 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4026756	19900824

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marquis, Melvyn I.
ASSISTANT EXAMINER: Harrison, Robert H.
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:86278 USPATFULL
TI Preservatives and their use
IN Eggensperger, Heinz, Hamburg, Germany, Federal Republic of
Diehl, Karl-Heinz, Norderstedt, Germany, Federal Republic of
Oltmanns, Peter, Hamburg, Germany, Federal Republic of
PA Schulke & Mayr GmbH, Hamburg, Germany, Federal Republic of (non-U.S. corporation)
PI US 5670160 19970923
AI US 1996-649254 19960130 (8)
RLI Continuation of Ser. No. US 1993-115298, filed on 1 Sep 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-741008, filed on 6 Aug 1991, now abandoned
PRAI DE 1990-4026756 19900824
DT Utility
FS Granted
EXNAM Primary Examiner: Marquis, Melvyn I.; Assistant Examiner: Harrison, Robert H.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A preservative, for compositions having an aqueous phase, comprising

a) 5 to 60% by weight of an organic acid selected from the group consisting of benzoic acid, 4-hydroxybenzoic acid, salicylic acid, formic acid, acetic acid, propionic acid, sorbic acid, undecylenic acid and dehydracetic acid or their mixtures including their sodium, potassium, calcium, magnesium, ammonium and ethanolamine salts

b) 10 to 95% by weight of alcohols of the general formulae I, II or III ##STR1## in which R.sub.1 denotes hydrogen, an n-alkyl, iso-alkyl or alkoxy radical having 1 to 3 C atoms, and R.sub.2 and R.sub.3 denote hydrogen or a CH.sub.3 -- or C.sub.2 H.sub.5 -- radical and n has the value of 3 or 4, and

c) 0.1 to 20% by weight of one or more poly(hexa-methylenebiguanide) salts of the general formula ##STR2## in which Z represents hydrochloride, acetate, lactate, benzoate, propionate, 4-hydroxybenzoate, sorbate or salicylate; and n has the value of 4 to 6, in combination in a customary carrier or solvent.

L10 ANSWER 46 OF 65 USPATFULL

ACCESSION NUMBER:	97:51865 USPATFULL
TITLE:	Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m
INVENTOR(S):	Mitsuhashi, Masato, Irvine, CA, United States Cooper, Allan, Bellview, WA, United States
PATENT ASSIGNEE(S):	Hitachi Chemical Company, Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5639612		19970617
APPLICATION INFO.:	US 1995-379078		19950126 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-974406, filed on 12 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922522, filed on 28 Jul 1992, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Horlick, Kenneth R.
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear
NUMBER OF CLAIMS:	37
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	65 Drawing Figure(s); 63 Drawing Page(s)
LINE COUNT:	5724

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN	97:51865 USPATFULL
TI	Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m
IN	Mitsuhashi, Masato, Irvine, CA, United States Cooper, Allan, Bellview, WA, United States
PA	Hitachi Chemical Company, Ltd., Tokyo, Japan (non-U.S. corporation)
PI	US 5639612 19970617
AI	US 1995-379078 19950126 (8)
RLI	Continuation of Ser. No. US 1992-974406, filed on 12 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922522, filed on 28 Jul 1992, now abandoned
DT	Utility
FS	Granted
EXNAM	Primary Examiner: Horlick, Kenneth R.
LREP	Knobbe, Martens, Olson & Bear
CLMN	Number of Claims: 37
ECL	Exemplary Claim: 1
DRWN	65 Drawing Figure(s); 63 Drawing Page(s)
LN.CNT	5724

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for detecting the presence of a particular organism, infectious agent, or biological component of a cell or organism in a sample, based on sandwich hybridization in which first and second probes are used, and the specificity of the first probe is determined based on its melting temperature (T.sub.m) with the target polynucleotide at a selected sodium and formamide concentration.

L10 ANSWER 47 OF 65 USPATFULL
ACCESSION NUMBER: 97:36345 USPATFULL
TITLE: Esters of acyl L-carnitines and pharmaceutical compositons containing same for treating endotoxic shock
INVENTOR(S): Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria O., Rome, Italy
Scafetta, Nazareno, Pavona di Albano, Italy
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5625085		19970429
APPLICATION INFO.:	US 1994-274686		19940714 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1993-RM468	19930714

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:36345 USPATFULL
TI Esters of acyl L-carnitines and pharmaceutical compositons containing same for treating endotoxic shock
IN Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria O., Rome, Italy
Scafetta, Nazareno, Pavona di Albano, Italy
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)
PI US 5625085 19970429
AI US 1994-274686 19940714 (8)
PRAI IT 1993-RM468 19930714
DT Utility
FS Granted
EXNAM Primary Examiner: Shippen, Michael L.
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, straight or branched alkanoyl having 2-26 carbon atoms, optionally .omega.-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

L10 ANSWER 48 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 97:368347 SCISEARCH
THE GENUINE ARTICLE: WX501
TITLE: Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides
AUTHOR: Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)

CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA
COUNTRY OF AUTHOR: SPAIN; INDIA
SOURCE: PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0196-9781.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 54
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 97:368347 SCISEARCH
GA The Genuine Article (R) Number: WX501
TI Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides
AU Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA
CYA SPAIN; INDIA
SO PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0196-9781.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 54
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The effects of CCK-8s and desulfated CCK-8 at concentrations ranging from 10-(14) to 10(-6) M were studied in vitro on several functions of human peripheral neutrophils: adherence to substrate, mobility (spontaneous and directed by a chemical gradient or chemotaxis), ingestion of inert particles (latex beads) or cells (**Candida albicans**), and production of superoxide anion measured by the nitroblue tetrazolium reduction test. The effect of CCK-8s on intracellular levels of cAMP was investigated as well as the implication of calcium in the action of CCK-8s on phagocytic function using stimulants and inhibitors of both intracellular and extracellular calcium channels. The two peptides, at concentrations from 10-(12) to 10(-8) M, inhibited significantly both mobility and ingestion capacities and increased adherence to substrate. A dose-response relationship was observed with a maximum inhibition of neutrophil functions at 10(-10) M. CCK-8s and desulfated CCK-8 induced in these cells a significant, but transient, increase of cAMP levels at 60 s. Moreover, CCK-8s was found to inhibit completely the stimulation of latex bead phagocytosis in neutrophils produced by the calcium ionophore A23187. These results suggest that CCK-8 is a negative modulator of several neutrophil functions and that the inhibition of these activities could be carried out through an increase of the intracellular cAMP levels and a decrease of the extracellular calcium input. (C) 1997 Elsevier Science Inc.

L10 ANSWER 49 OF 65 USPATFULL
ACCESSION NUMBER: 96:108816 USPATFULL
TITLE: Sequence-directed DNA-binding molecules compositions and methods
INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States

Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578444		19961126
APPLICATION INFO.:	US 1993-171389		19931220 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Atzel, Amy
LEGAL REPRESENTATIVE: Fabian, Gary R., Brookes, Allen A., Stratford, Carol A.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 71 Drawing Figure(s); 48 Drawing Page(s)
LINE COUNT: 5845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 96:108816 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5578444 19961126
AI US 1993-171389 19931220 (8)
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Brookes, Allen A., Stratford, Carol A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 48 Drawing Page(s)
LN.CNT 5845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 50 OF 65 USPATFULL
ACCESSION NUMBER: 96:38884 USPATFULL

TITLE: Immunological activity of rhamnolipids
INVENTOR(S): Piljac, Goran, 2323 Shasta Dr., Apt 40, Davis, CA, United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt 40, Davis, CA, United States 95616

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5514661		19960507
APPLICATION INFO.:	US 1995-520076		19950828 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-277975, filed on 20 Feb 1994, now patented, Pat. No. US 5466675 which is a continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 96:38884 USPATFULL
TI Immunological activity of rhamnolipids
IN Piljac, Goran, 2323 Shasta Dr., Apt 40, Davis, CA, United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt 40, Davis, CA, United States 95616
PI US 5514661 19960507
AI US 1995-520076 19950828 (8)
RLI Division of Ser. No. US 1994-277975, filed on 20 Feb 1994, now patented, Pat. No. US 5466675 which is a continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;

R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;

R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl and

R.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl; are provided.

L10 ANSWER 51 OF 65 USPATFULL
ACCESSION NUMBER: 95:101209 USPATFULL
TITLE: Immunological activity of rhamnolipids
INVENTOR(S): Piljac, Goran, 2323 Shasta Dr., Apt. 40, Davis, CA, United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt. 40, Davis, CA, United States 95616

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5466675 19951114
APPLICATION INFO.: US 1994-277975 19940720 (8)
DISCLAIMER DATE: 20090410
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	BE 1992-115	19920204

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:101209 USPATFULL
TI Immunological activity of rhamnolipids
IN Piljac, Goran, 2323 Shasta Dr., Apt. 40, Davis, CA, United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt. 40, Davis, CA, United States 95616
PI US 5466675 19951114
AI US 1994-277975 19940720 (8)
DCD 20090410
RLI Continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992, now abandoned
PRAI BE 1992-115 19920204
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;

R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;

R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl and

R.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;

are provided.

L10 ANSWER 52 OF 65 USPATFULL
ACCESSION NUMBER: 95:82344 USPATFULL
TITLE: Prolyl endopeptidase inhibitors SNA-115 and SNA-115T, and process for the production and productive strain thereof
INVENTOR(S): Kimura, Kenichi, Tochigi, Japan
Kanou, Fumiko, Tochigi, Japan
Takahashi, Hidetoshi, Tochigi, Japan
Kurosawa, Kazuhiko, Tochigi, Japan
Yoshihama, Makoto, Tochigi, Japan
PATENT ASSIGNEE(S): Snow Brand Milk Products Co., Ltd., Hokkaido, Japan

(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5449750		19950912	
	WO 9300361		19930701	
APPLICATION INFO.:	US 1993-977444		19930217	(7)
	WO 1992-JP784		19920619	
			19930217	PCT 371 date
			19930217	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-176228	19910620
	JP 1992-78262	19920228

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Jill
ASSISTANT EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Burgess, Ryan & Wayne
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 641
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:82344 USPATFULL

TI Prolyl endopeptidase inhibitors SNA-115 and SNA-115T, and process for the production and productive strain thereof

IN Kimura, Kenichi, Tochigi, Japan
Kanou, Fumiko, Tochigi, Japan
Takahashi, Hidetoshi, Tochigi, Japan
Kurosawa, Kazuhiko, Tochigi, Japan
Yoshihama, Makoto, Tochigi, Japan

PA Snow Brand Milk Products Co., Ltd., Hokkaido, Japan (non-U.S. corporation)

PI US 5449750 19950912
WO 9300361 19930701

AI US 1993-977444 19930217 (7)
WO 1992-JP784 19920619
19930217 PCT 371 date
19930217 PCT 102(e) date

PRAI JP 1991-176228 19910620
JP 1992-78262 19920228

DT Utility
FS Granted
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Wessendorf, T. D.
LREP Burgess, Ryan & Wayne
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 641
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Prolyl endopeptidase inhibiting compounds SNA-115 and SNA-115T are provided having molecular formulas of C.sub.113 H.sub.142 N.sub.26 O.sub.27 and C.sub.113 H.sub.144 N.sub.26 O.sub.28 respectively. SNA-115T has the following structural formula:

Arg Tyr Asp Trp Trp Pro Tyr Gly Asp Leu Phe Gly Gly His Thr Phe Ile Ser Pro

Processes are also provided for the production of SNA-11 by culturing the SNA productive microorganism and production of SNA-115T by degradation of SNA-115 with trypsin. Both SNA-115 and SNA-115T exhibit prolyl endopeptidase inhibitory properties.

L10 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:237581 CAPLUS
DOCUMENT NUMBER: 120:237581
TITLE: Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification
INVENTOR(S): Mitsuhashi, Masato; Cooper, Allan
PATENT ASSIGNEE(S): Hitachi Chemical Company Ltd., Japan
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402636	A1	19940203	WO 1993-US999	19930129
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 652971	A1	19950517	EP 1993-905793	19930129
R: CH, DE, FR, GB, IT, LI				
JP 07509361	T2	19951019	JP 1993-504409	19930129
US 5580971	A	19961203	US 1995-379081	19950126
US 5639612	A	19970617	US 1995-379078	19950126
PRIORITY APPLN. INFO.:			US 1992-922522	19920728
			US 1992-974406	19921112
			WO 1993-US999	19930129

AN 1994:237581 CAPLUS
DN 120:237581
TI Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification
IN Mitsuhashi, Masato; Cooper, Allan
PA Hitachi Chemical Company Ltd., Japan
SO PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9402636	A1	19940203	WO 1993-US999	19930129
	W: CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 652971	A1	19950517	EP 1993-905793	19930129
	R: CH, DE, FR, GB, IT, LI				
	JP 07509361	T2	19951019	JP 1993-504409	19930129
	US 5580971	A	19961203	US 1995-379081	19950126
	US 5639612	A	19970617	US 1995-379078	19950126
PRAI	US 1992-922522		19920728		
	US 1992-974406		19921112		
	WO 1993-US999		19930129		

AB A method for detecting the presence of a particular organism, infectious agent, or component of a cell or organism in a biol. sample by nucleic acid hybridization is described. A hybridization probe for the target sequence is immobilized on a solid support, such as microtiter well, and the target sequence is then hybridized to the immobilized probe. A second, labeled probe is then hybridized to this support-polynucleotide structure and binding of this probe is used to quantify the target sequence. Sensitivity of the system may be improved by amplification of the bound or free target polynucleotide. Also included in the present invention are polynucleotide probes and primers and the use of an H-site model and algorithm for the design of these probes and primers with an

optimized matching of Tm's based upon related sequences available in data banks.

L10 ANSWER 54 OF 65 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95024893 EMBASE
DOCUMENT NUMBER: 1995024893
TITLE: High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.
AUTHOR: Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.
CORPORATE SOURCE: Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy
SOURCE: Pediatric Allergy and Immunology, (1994) 5/4 (240-243). ISSN: 0905-6157 CODEN: PALUEE
COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 95024893 EMBASE
DN 1995024893
TI High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.
AU Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.
CS Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy
SO Pediatric Allergy and Immunology, (1994) 5/4 (240-243). ISSN: 0905-6157 CODEN: PALUEE
CY Denmark
DT Journal; Article
FS 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation
LA English
SL English
AB The specificity of IgA against food, inhalant, bacterial and fungine antigens as well as for HIV-1 proteins was investigated in 14 HIV-1-infected children (CDC stage P-2) and 15 controls. IgA against food- and inhalant antigens as well as against tetanus toxoid were significantly more often present in the HIV positive children than in controls. No difference between the two groups was present for IgA against **Candida albicans**. A significant increase of **substance P**, a strong IgA synthesis inducing neuropeptide, was demonstrated in the plasma of HIV-1 infected children. In conclusion, high levels of IgA seem to reflect a complex immune dysfunction in which many factors are involved. The importance of neuroimmune dysregulation is discussed.

L10 ANSWER 55 OF 65 USPATFULL
ACCESSION NUMBER: 93:74284 USPATFULL
TITLE: Defensin peptide compositions and methods for their use
INVENTOR(S): Murphy, Christopher J., Davis, CA, United States
Reid, Ted W., Davis, CA, United States
Mannis, Mark J., Carmichael, CA, United States
Foster, Bradley A., Davis, CA, United States
Cullor, James S., Woodland, CA, United States
Selsted, Michael E., Los Angeles, CA, United States
Lehrer, Robert I., Santa Monica, CA, United States
Ganz, Tomas, Los Angeles, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,

CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5242902		19930907
APPLICATION INFO.:	US 1989-404249		19890906 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Townsend and Townsend Khourie and Crew
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 702
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 93:74284 USPATFULL
TI Defensin peptide compositions and methods for their use
IN Murphy, Christopher J., Davis, CA, United States
Reid, Ted W., Davis, CA, United States
Mannis, Mark J., Carmichael, CA, United States
Foster, Bradley A., Davis, CA, United States
Cullor, James S., Woodland, CA, United States
Selsted, Michael E., Los Angeles, CA, United States
Lehrer, Robert I., Santa Monica, CA, United States
Ganz, Tomas, Los Angeles, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5242902 19930907
AI US 1989-404249 19890906 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Townsend and Townsend Khourie and Crew
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 702
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating cutaneous and corneal wounds as well as certain microbial-related diseases comprises topically applying a defensin peptide to the affected tissue. The compositions comprise a natural, synthetic, or analog defensin molecule having both a mitogenic activity capable of stimulating cell growth and an antimicrobial activity capable of inhibiting the growth of a wide variety of pathogens. In addition to therapeutic use, the defensins are useful as mitogens in cell and tissue culture media.

L10 ANSWER 56 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 93:689339 SCISEARCH
THE GENUINE ARTICLE: MF885
TITLE: STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT
AUTHOR: DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A; GOMARIZ R P
CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3, SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR, MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN
COUNTRY OF AUTHOR: SPAIN
SOURCE: REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353.
ISSN: 0167-0115.
DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 44
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 93:689339 SCISEARCH
GA The Genuine Article (R) Number: MF885
TI STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT
AU DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A; GOMARIZ R P
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3, SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR, MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353. ISSN: 0167-0115.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 44
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The action of vasoactive intestinal peptide (VIP) on macrophages has not yet been studied, although there are studies that show an inhibitory action of VIP on lymphocyte functions. The present study shows that VIP in a range from 10(-12) to 10(-7) M increased significantly the phagocytosis and digestion capacities of rat peritoneal macrophages. The most effective concentration of VIP was 10(-9) M followed by 10(-8) M. With respect to the phagocytic capacity, the ingestion of cells (**Candida albicans**) or inert particles (latex beads) was stimulated significantly with all the concentrations used. The digestion capacity was analyzed through the production of superoxide anion, measured by the reduction of nitroblue tetrazolium (NBT). As with phagocytic capacity, superoxide anion production was increased by VIP in non-stimulated macrophages (incubated without latex beads) and even more in stimulated cells (incubated in the presence of latex beads). The study of the mechanism of action of this neuropeptide showed that protein kinase C (PKC) was activated in the presence of VIP concentrations from 10(-10) to 10(-8) M in a similar way to that found with a specific PKC activator such as phorbol myristate acetate (PMA, 50 ng/ml). PMA also stimulated significantly the phagocytosis and digestion capacities of rat macrophages. By contrast, a PKC inhibitor, retinal (20 muM), decreased significantly the phagocytosis and digestion capacities. These data show that VIP could stimulate these macrophage functions through PKC activation.

L10 ANSWER 57 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 93:606596 SCISEARCH
THE GENUINE ARTICLE: LZ829
TITLE: STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF PROTEIN-KINASE-C
AUTHOR: DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CORPORATE SOURCE: UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ INSALUD, SERV BIOQUIM, MADRID, SPAIN
COUNTRY OF AUTHOR: SPAIN
SOURCE: IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265. ISSN: 0019-2805.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 38
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 93:606596 SCISEARCH

GA The Genuine Article (R) Number: LZ829
TI STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF PROTEIN-KINASE-C
AU DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CS UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ INSALUD, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265.
ISSN: 0019-2805.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 38
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The peptides neuropeptide Y (NPY) and peptide YY (PYY) at concentrations from 10(-12) M to 10(-8) M have been shown in this study to stimulate significantly, in vitro, several functions of resting peritoneal macrophages from BALB/c mice: adherence to substrate, chemotaxis, ingestion of inert particles (latex beads) and foreign cells (**Candida albicans**), and production of superoxide anion measured by nitroblue tetrazolium reduction. A dose-response relationship was observed, with a maximal stimulation of the macrophage functions studied at 10(-10) M. These effects seem to be produced by specific receptors for the neuropeptides studied in peritoneal macrophages. Whereas the two peptides induced no change of intracellular cyclic AMP, they caused a significant stimulation of protein kinase C (PKC) in murine macrophages. These results suggest that NPY and PYY produce their effects on macrophage function through PKC activation.

L10 ANSWER 58 OF 65 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1993:500498 BIOSIS
DOCUMENT NUMBER: PREV199396124505
TITLE: Inhibition of murine intestinal inflammation by anti-**substance P** antibody.
AUTHOR(S): Agro, Albert; Stanisz, Andrzej M. (1)
CORPORATE SOURCE: (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada
SOURCE: Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
ISSN: 0896-0623.
DOCUMENT TYPE: Article
LANGUAGE: English
AN 1993:500498 BIOSIS
DN PREV199396124505
TI Inhibition of murine intestinal inflammation by anti-**substance P** antibody.
AU Agro, Albert; Stanisz, Andrzej M. (1)
CS (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada
SO Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
ISSN: 0896-0623.
DT Article
LA English
AB Several neuropeptides have recently been shown to affect various aspects of the inflammatory process. Among these, the neuropeptide **substance P** posseses a host of immune modifying actions, which include the enhancement of lymphocyte activity, macrophage function, and neutrophil chemotaxis. The role of **substance P** during inflamed states has, as yet, not been fully described. Here, in T. spiralis-infected mice, we parallel increased levels of **substance P** both locally, (the gut) and peripherally (serum) with decreased lymphocyte responsiveness. Upon the introduction of in vivo antisubstance P antibody during the infection, levels of **substance P** , gastrointestinal inflammation, and lymphocyte proliferation are significantly restored to baseline (noninfected) levels. These findings

suggest that the neuropeptide **substance P** plays an important role in promoting inflammation. It also offers the basis for future pharmacological interventions.

L10 ANSWER 59 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 91:430018 SCISEARCH
THE GENUINE ARTICLE: FY390
TITLE: RETENTION OF AMPHOTERICIN-B THERAPEUTIC EFFICACY AT HALF DOSES BY SYNERGISTIC ACTIVATION OF PHAGOCYTES
AUTHOR: CORNAGLIAFERRARIS P (Reprint); ROSSI E; PEREZZANI L; STRADI R
CORPORATE SOURCE: GASLINI CHILDRENS HOSP, PEDIAT ONCOL RES LAB, L GO G GASLINI 5, I-16148 GENOA, ITALY (Reprint)
COUNTRY OF AUTHOR: ITALY
SOURCE: CANCER DETECTION AND PREVENTION, (1991) Vol. 15, No. 4, pp. 327-329.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: CLIN
LANGUAGE: ENGLISH
REFERENCE COUNT: No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 91:430018 SCISEARCH
GA The Genuine Article (R) Number: FY390
TI RETENTION OF AMPHOTERICIN-B THERAPEUTIC EFFICACY AT HALF DOSES BY SYNERGISTIC ACTIVATION OF PHAGOCYTES
AU CORNAGLIAFERRARIS P (Reprint); ROSSI E; PEREZZANI L; STRADI R
CS GASLINI CHILDRENS HOSP, PEDIAT ONCOL RES LAB, L GO G GASLINI 5, I-16148 GENOA, ITALY (Reprint)
CYA ITALY
SO CANCER DETECTION AND PREVENTION, (1991) Vol. 15, No. 4, pp. 327-329.
DT Article; Journal
FS CLIN
LA ENGLISH
REC No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Amphotericin B (AMB) is a mainstay in the treatment of serious systemic fungal infections, such as those occurring prevalently in immuno-compromised patients treated with immunosuppressive agents or affected by Acquired Immunodeficiency Syndrome (AIDS). However AMB is an extremely toxic agent whose therapeutical utilization is often accompanied by acute side effects and chronic impairment of renal function. It is here reported that the preactivation of polymorphonucleated cells (PMN) in vivo, by a new immunomodulatory agent (PCF 39:N alpha-5[1,6,dhydro-(6-oxo-9 purinyl) pentoxycarbonyl]-L-Arginine) allows marked reduction of the AMB doses with full retention of therapeutic efficacy. This was observed in an experimental fungal infection induced in mice by intravenous inoculation of **Candida albicans**.

L10 ANSWER 60 OF 65 USPATFULL
ACCESSION NUMBER: 87:20665 USPATFULL
TITLE: N-substituted diaminopropane/glutamic acid reaction products
INVENTOR(S): Gerhardt, Werner, Hilden, Germany, Federal Republic of
Fischer, Herbert, Duesseldorf, Germany, Federal Republic of
Lehmann, Rudolf, Leichlingen, Germany, Federal Republic of
Disch, Karlheinz, Haan, Germany, Federal Republic of
Leinen, Hans T., Aachen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Henkel Kommanditgesellschaft auf Aktien, Duesseldorf, Germany, Federal Republic of (non-U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 4652585 19870324
APPLICATION INFO.: US 1985-713126 19850315 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1984-3410956	19840324

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Szoke, Ernest G., Millson, Jr., Henry E., Greenfield, Mark A.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1,16
LINE COUNT: 700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 87:20665 USPATFULL
TI N-substituted diaminopropane/glutamic acid reaction products
IN Gerhardt, Werner, Hilden, Germany, Federal Republic of
Fischer, Herbert, Duesseldorf, Germany, Federal Republic of
Lehmann, Rudolf, Leichlingen, Germany, Federal Republic of
Disch, Karlheinz, Haan, Germany, Federal Republic of
Leinen, Hans T., Aachen, Germany, Federal Republic of
PA Henkel Kommanditgesellschaft auf Aktien, Duesseldorf, Germany, Federal Republic of (non-U.S. corporation)
PI US 4652585 19870324
AI US 1985-713126 19850315 (6)
PRAI DE 1984-3410956 19840324
DT Utility
FS Granted
EXNAM Primary Examiner: Shippen, Michael L.
LREP Szoke, Ernest G., Millson, Jr., Henry E., Greenfield, Mark A.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1,16
DRWN No Drawings
LN.CNT 700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds which are the reaction products of a C.sub.12-14 -alkyl N-substituted 1,3-diaminopropane and glutamic acid or its 5-methyl ester, optionally alkoxylated, and optionally their salts, are useful as antimicrobial agents.

L10 ANSWER 61 OF 65 CABA COPYRIGHT 2002 CABI
ACCESSION NUMBER: 88:14558 CABA
DOCUMENT NUMBER: 881340734
TITLE: Inhibitory effects of levamisole- and tetramisole-hydrochloride (in vitro) on Prototheca zopfii and **Candida albicans**
Hemmwirkung von Levamisol- und Tetramisolhydrochlorid in vitro gegen Prototheca zopfii und **Candida albicans**
AUTHOR: Bergmann, A.
CORPORATE SOURCE: Wissenchaftsbereich Microbiologie und Tierseuchen, Sektion Tierproduction und Veterinarmedizin der Karl-Marx Universitat, Leipzig, German Democratic Republic.
SOURCE: Monatshefte fur Veterinarmedizin, (1987) Vol. 42, No. 16, pp. 599-602. 7 ref.
DOCUMENT TYPE: Journal
LANGUAGE: German
SUMMARY LANGUAGE: English; Russian
AN 88:14558 CABA
DN 881340734
TI Inhibitory effects of levamisole- and tetramisole-hydrochloride (in vitro) on Prototheca zopfii and **Candida albicans**

Hemmwirkung von Levamisol- und Tetramisolhydrochlorid in vitro gegen Prototheca zopfii und **Candida albicans**

AU Bergmann, A.

CS Wissenchaftsbereich Microbiologie und Tierseuchen, Sektion Tierproduction und Veterinarmedizin der Karl-Marx Universitat, Leipzig, German Democratic Republic.

SO Monatshefte fur Veterinarmedizin, (1987) Vol. 42, No. 16, pp. 599-602. 7 ref.

DT Journal

LA German

SL English; Russian

AB Agar gel and paper disc diffusion tests were performed on 5 P. zopfii strs. obtained from cases of mastitis and 5 C. **albicans** strs. obtained from pathological material from various animal species. Levamisol hydrochloride was clearly shown to be the better of the 2 active **substances**. **P.** zopfii proved to be more sensitive than C. **albicans**. A comparison of the paper disc diffusion test with antifungal agents used in human medicine revealed that 4 of 5 P. zopfii strs. were more sensitive to tetramisol hydrochloride. Levamisol hydrochloride was found to be superior to nystatin in its action against C. **albicans**, but less so when compared with amphotericin B. Miconazole showed no antifungal effect against all P. zopfii strs.

L10 ANSWER 62 OF 65 USPATFULL

ACCESSION NUMBER: 84:18660 USPATFULL

TITLE: Pharmaceutical composition comprising derivative of aminobenzoic acid for regulating prostaglandin

INVENTOR(S): Yoshikumi, Chikao, Kunitachi, Japan
Ohmura, Yoshio, Funabashi, Japan
Hirose, Fumio, Tokyo, Japan
Ikuzawa, Masanori, Tachikawa, Japan
Matsunaga, Kenichi, Tokyo, Japan
Fujii, Takayoshi, Tokyo, Japan
Ohhara, Minoru, Tokyo, Japan
Ando, Takao, Tokyo, Japan

PATENT ASSIGNEE(S): Kureha Kagaku Kogyo Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4440757		19840403
APPLICATION INFO.:	US 1980-174543		19800801 (6)

DISCLAIMER DATE: 19990202

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1979-84467, filed on 12 Oct 1979, now patented, Pat. No. US 4322409 And a continuation-in-part of Ser. No. US 1979-81190, filed on 10 Feb 1979, now patented, Pat. No. US 4322408 And a continuation-in-part of Ser. No. US 1979-102535, filed on 11 Dec 1979, now patented, Pat. No. US 4313939 And a continuation-in-part of Ser. No. US 1979-102224, filed on 10 Dec 1979, now patented, Pat. No. US 4315921 , said Ser. No. 84467

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-40594	19780406
	JP 1978-42014	19780410
	JP 1978-42015	19780410
	JP 1978-42576	19780411
	JP 1978-63146	19780526
	JP 1978-161385	19781229
	JP 1978-161386	19781229
	JP 1980-91113	19800705

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Wegner & Bretschneider
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1,5
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 84:18660 USPATFULL
TI Pharmaceutical composition comprising derivative of aminobenzoic acid for regulating prostaglandin
IN Yoshikumi, Chikao, Kunitachi, Japan
Ohmura, Yoshio, Funabashi, Japan
Hirose, Fumio, Tokyo, Japan
Ikuzawa, Masanori, Tachikawa, Japan
Matsunaga, Kenichi, Tokyo, Japan
Fujii, Takayoshi, Tokyo, Japan
Ohhara, Minoru, Tokyo, Japan
Ando, Takao, Tokyo, Japan
PA Kureha Kagaku Kogyo Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)
PI US 4440757 19840403
AI US 1980-174543 19800801 (6)
DCD 19990202
RLI Continuation-in-part of Ser. No. US 1979-84467, filed on 12 Oct 1979, now patented, Pat. No. US 4322409 And a continuation-in-part of Ser. No. US 1979-81190, filed on 10 Feb 1979, now patented, Pat. No. US 4322408 And a continuation-in-part of Ser. No. US 1979-102535, filed on 11 Dec 1979, now patented, Pat. No. US 4313939 And a continuation-in-part of Ser. No. US 1979-102224, filed on 10 Dec 1979, now patented, Pat. No. US 4315921 , said Ser. No. 84467
PRAI JP 1978-40594 19780406
JP 1978-42014 19780410
JP 1978-42015 19780410
JP 1978-42576 19780411
JP 1978-63146 19780526
JP 1978-161385 19781229
JP 1978-161386 19781229
JP 1980-91113 19800705
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Wegner & Bretschneider
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,5
DRWN 16 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition for regulating prostagrandins, which comprises (a) a derivative of aminobenzoic acid, represented by the following general formula: ##STR1## wherein R.sup.1 denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha)-or 1(beta) position from arabinose, xylose, rhamnose, glucose, galactose, mannose and fructose, and R.sup.2 is a hydrogen atom, an alkyl group of one to four carbon atoms or a pharmaceutically acceptable metal, and (b) a pharmaceutically acceptable carrier or diluent of (a) is disclosed.

L10 ANSWER 63 OF 65 USPATFULL
ACCESSION NUMBER: 78:45570 USPATFULL
TITLE: Method for preparing antibiotic P-2563 using Pseudomonas fluorescens
INVENTOR(S): Nara, Kiyoshi, Kyoto, Japan
Sumino, Yasuhiro, Kobe, Japan

Asai, Mitsuko, Takatsuki, Japan
Akiyama, Shunichi, Suita, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4108724		19780822
APPLICATION INFO.:	US 1976-674310		19760407 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1975-15062	19750411

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, Raymond N.
ASSISTANT EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 78:45570 USPATFULL
TI Method for preparing antibiotic P-2563 using Pseudomonas fluorescens
IN Nara, Kiyoshi, Kyoto, Japan
Sumino, Yasuhiro, Kobe, Japan
Asai, Mitsuko, Takatsuki, Japan
Akiyama, Shunichi, Suita, Japan
PA Takeda Chemical Industries, Ltd., Japan (non-U.S. corporation)
PI US 4108724 19780822
AI US 1976-674310 19760407 (5)
PRAI GB 1975-15062 19750411
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, Raymond N.; Assistant Examiner: Wiseman, Thomas G.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel antibiotic P-2563 is produced by cultivating a microorganism of the genus Pseudomonas.

The antibiotic is useful as a drug for the treatment of pustule, and also useful as a disinfectant.

L10 ANSWER 64 OF 65 USPATFULL
ACCESSION NUMBER: 76:35182 USPATFULL
TITLE: Antimicrobial agents for water conservation
INVENTOR(S): Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Rhineland, Germany, Federal Republic of
PATENT ASSIGNEE(S): Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3965265		19760622

APPLICATION INFO.: US 1975-542229 19750120 (5)
RELATED APPLN. INFO.: Division of Ser. No. US 1973-352941, filed on 20 Apr 1973, now patented, Pat. No. US 3874869

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2220026	19720424
	DE 1973-2314221	19730322

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ore, Dale R.
LEGAL REPRESENTATIVE: Hammond & Littell
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 76:35182 USPATFULL
TI Antimicrobial agents for water conservation
IN Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Rhineland, Germany, Federal Republic of
PA Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of (non-U.S. corporation)
PI US 3965265 19760622
AI US 1975-542229 19750120 (5)
RLI Division of Ser. No. US 1973-352941, filed on 20 Apr 1973, now patented, Pat. No. US 3874869
PRAI DE 1972-2220026 19720424
DE 1973-2314221 19730322
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Hammond & Littell
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for the prevention of the growth of microorganisms, especially in industrial water, comprises contacting these microorganisms with an effective antimicrobial amount of a reaction product of .epsilon.-caprolactam and an N-alkylalkylene diamine with the reaction being carried out in the liquid phase for 3 to 20 hours at a temperature about 180.degree.C. The process further comprises incorporating into said industrial water an effective amount of a sequestering agent comprising a water-soluble phosphonic acid which forms a complex with a divalent metal, a water-soluble salt of the acid and the mixtures thereof, with the weight ratio of sequestering agent to reaction product being 1:10 to 10:1.

L10 ANSWER 65 OF 65 USPATFULL
ACCESSION NUMBER: 75:16586 USPATFULL
TITLE: Antimicrobial agents for water conservation
INVENTOR(S): Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Germany, Federal Republic of
PATENT ASSIGNEE(S): Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3874869		19750401

APPLICATION INFO.: US 1973-352941 19730420 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2220026	19720424
	DE 1973-2314221	19730322

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hollrah, Glennon H.
LEGAL REPRESENTATIVE: Hammond & Littell
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 75:16586 USPATFULL
TI Antimicrobial agents for water conservation
IN Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Germany, Federal Republic of
PA Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of
(non-U.S. corporation)
PI US 3874869 19750401
AI US 1973-352941 19730420 (5)
PRAI DE 1972-2220026 19720424
DE 1973-2314221 19730322
DT Utility
FS Granted
EXNAM Primary Examiner: Hollrah, Glennon H.
LREP Hammond & Littell
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the prevention of the growth of microorganisms, especially in industrial water, comprises contacting these microorganisms with an effective antimicrobial amount of a reaction product of .epsilon.-caprolactam and an N-alkylalkylene diamine with the reaction being carried out in the liquid phase for 3 to 20 hours at a temperature above 180.degree.C. The process further comprises incorporating into said industrial water an effective amount of a sequestering agent comprising a water-soluble phosphonic acid which forms a complex with a divalent metal, a water-soluble salt of the acid and the mixtures thereof, with the weight ratio of sequestering agent to reaction product being 1:10 to 10:1.

=>

=>